






MODELING CHARCOT MARIE TOOTH 1A  










A dissertation submitted to Johns Hopkins University in conformity with the 












 We have developed a defined protocol for the direct derivation and 
prospective isolation of Schwann cells from human embryonic and induced 
pluripotent stem cells.  Potential uses of these cells include disease modeling, drug 
screening, and transplantation therapy, making it an exciting platform for 
translational research and personalized medicine.  This method was applied to 
model CMT1A, a genetic peripheral neuropathy characterized by a 1.4 MB 
duplication on chromosome 14.  Results from profiling CMT1A hiPSC-Schwann cells 
were validated using CMT1A PGD-hESC-Schwann cells and CMT1A iNC-Schwann 
cells.  All three models displayed increased expression of the Peripheral Myelin 
Protein (PMP22) transcript, the gene believed to cause CMT1A.  Two of the three 
models demonstrated upregulated expression of the heparan sulfate biosynthesis 
gene, HS3ST3b1, which is also located in the 1.4 MB CMT1A duplicated region, 
plays a rate limiting role in heparan sulfate fine structure biosynthesis, and whose 
specific role in Schwann cells is yet to be determined.  Most interestingly, two pro-
inflammatory cytokines, CXCL1 and MCP-1 proteins, were ultimately commonly 
overexpressed in all three models, and their overexpression was also confirmed in 
nerve biopsies from two CMT1A patients.  It was also found that CMT1A Schwann 
cells of all three models could more readily recruit human THP-1 monocytes, and 
that this recruitment occurred in an MCP-1 dependent manner.  Finally, through 
treatment with three small molecules previously identified to decrease PMP22 gene 




and MCP-1 protein expression in Schwann cells from hiPSCs from one patient, in an 
example of how hiPSC-derived Schwann cells may be used for patient-specific 
therapeutic studies going forward. 
These results imply pro-inflammatory cytokine release may comprise an 
intrinsic and early property of nascent Schwann cells, and that immune 
dysregulation may be an early contributor to CMT1A pathogenesis, as opposed to a 
secondary reaction.  Finally, the broadest contribution of this study is a 
methodological one, in which all three reprogrammed Schwann cell models were 
utilized to demonstrate a converged phenotype.  This approach offers a technical 
alternative to genome editing for disease hiPSC phenotype validation, and 
comprises a feasible model for future studies.   
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Schwann cell development and engineering 
 Schwann cells are the myelinating and non-myelinating glia of the peripheral 
nervous system.  They one of many derivatives of neural crest, a multipotent cell 
type that delaminates from the dorsal neural tube and migrates throughout the 
body to give rise to specialized cell types1.  Neural crest along different positions on 
the anterior-posterior axis give rise to different cell types.  Most anteriorly, cranial 
neural crest form the craniofacial bones, cartilage, and ganglia.  Trunk neural crest 
give rise to the dorsal root ganglia, Schwann cells, sympathetic ganglia, adrenal 
medulla, and melanocytes.  The cardiac neural crest generate neurons, 
melanocytes, fibroblasts, chondrocytes, and also play a role in cardiac septation.  
Finally the vagal and sacral neural crest create the enteric nervous system and 
parasympathetic ganglia2,3.   
 Schwann cell development from neural crest occurs over a number of 
embryonic and postnatal transitions.  During embryonic gliogenesis, the neural 
crest first give rise to the Schwann cell precursor (seen at rat E14/15), which can 
be distinguished from neural crest by its expression of Myelin Protein Zero and 
Cadherin 19.  At this stage, the Schwann cell precursors (SCPs) are associated with 
axons, and the neurons and SCPs are mutually dependent for survival.  In 
particular, it appears Neuregulin 1 type III (NRG1-III) is the relevant axon-
associated signal that permits Schwann cell precursor survival4,5.   
Around rat E17/18, the Schwann cell precursors evolve into immature 
Schwann cells, and transition from merely being associated with axons to 




myelination, individual Schwann cells begin to surround large diameter axons in a 
1:1 ratio, in a process known as radial sorting.  These pro-myelinating Schwann 
cells will eventually develop into myelinating Schwann cells in a process requiring 
profound molecular changes, including activation of transcription factors Oct6, 
Krox20, and perhaps Brn2.  In contrast to the myelinated large diameter axons, 
some of the smaller diameter axons remain unmyelinated in Remak bundles and 
are surrounded by non-myelinating Schwann cells that continue to provide 
metabolic and trophic support4,5. 
 By mimicking the in vivo processes orchestrating Schwann cell development, 
we may be able to generate Schwann cells in vitro as well.  Major technological 
strides in biology now give us the ability to engineer cell types in vitro, either 
through directed differentiation from human pluripotent stem cells (hPSCs) 
(collectively, human embryonic stem cells and human induced pluripotent stem 
cells) or via direct lineage conversion from somatic cells (ie fibroblasts).  
Engineered or reprogrammed human Schwann cells are desirable for a number of 
applications including: 1) in vitro disease modeling, often in a patient-specific 
matter, 2) high throughput in vitro drug screening, possibly in a patient specific 
manner, and 3) cell transplantation therapy, possibly using patient-matched cells, 
although this goal is the most elusive of the three.   
 This thesis began four years ago, with the initial goal of developing a 
methodology for the efficient differentiation of Schwann cells from human 
pluripotent stem cells.  Over the course of this thesis, another such protocol has 




several advantages including: use of a 2D monolayer culture system (vs a 3D 
embryoid body or neurosphere culture system; a monolayer culture systems allow 
for more homogeneity in cell fate specification), direct differentiation into Schwann 
cells (as opposed to a 2 step method for neural crest differentiation, followed by 
Schwann cell differentiation), use of defined conditions and small molecules to 
activate developmentally relevant pathways in vitro, and a method for prospective 
isolation of resulting Schwann cells from the non-Schwann cells. 
In chapter 2, we detail that method for differentiating Schwann cells from 
human pluripotent cells.  In chapter 3, that method is applied to CMT1A patient-
derived hiPSCs, to better model the molecular pathways that may be aberrant in 
CMT1A patient Schwann cells.  In chapter 4, our hiPSC-based results are validated 
using engineered Schwann cells from two additional sources: IVF-derived 
blastocysts with a preimplantation genetic diagnosis (PGD-hESCs) of CMT1A and 
CMT1A patient fibroblasts that have been directly converted into induced neural 
crest (iNC) and subsequently differentiated into Schwann cells.  Overall this thesis 
makes contributions to both the stem cell and CMT1A fields through development of 
1) a defined protocol for Schwann cell derivation, 2) expression profiling of CMT1A 
hiPSC-Schwann cells, and 3) validation of the hiPSC data with CMT1A embryonic 
stem cell lines and CMT1A induced neural crest-derived Schwann cells. 
 
An overview of CMT1A 
 Charcot Marie Tooth disease (CMT), also known as Hereditary Motor and 




inherited peripheral neuropathies characterized by their progressive motor and 
sensory deficits and muscle wasting.   Combined, they affect an estimated 1 in 
2500 individuals, making them the most common inherited peripheral nervous 
system disorder in the world7.  The CMTs are categorized into various subtypes 
based on their genetic and clinical characteristics8.  CMT1 (HMSN1) comprises 
autosomal dominant demyelinating peripheral neuropathies in which Schwann cells 
are believed to be the pathological cell type; it is caused by mutations (and 
duplication in the case of peripheral myelin protein 22, PMP22) in genes related to 
myelination, such as PMP22, myelin protein zero (MPZ), early growth response 2 
(EGR2), and others.  CMT2 (HMSN2) is a primarily axonal neuropathy, clinically 
characterized by normal nerve conduction velocities, and genetically characterized 
by mutations in genes critical to neuronal function, such as mitofusin 2 (MFN2), ras 
associated protein 7 (RAB7), transient receptor potential cation channel subfamily V 
member 4 (TRPV4), and others.  HMSN3 is also known as Dejerine-Sottas 
Syndrome, a more rapidly progressive and severe demyelinating neuropathy than 
CMT1; it is also characterized by mutations in genes expressed in Schwann cells, ie 
PMP22, MPZ, EGR2, and others.  CMT4 (HMSN4) is also a demyelinating 
neuropathy, distinguished by its autosomal recessive inheritance pattern, and is 
caused by mutations in a diverse set of genes, such as ganglioside-induced 
differentiation-associated protein 1 (GDAP1), myotubularin related protein 2 
(MTMR2), myotubularin related protein 13 (MTMR13), sh3 domain and 
tetratricopeptide repeat domain 2 (SH3TC2), periaxin (PRX) and FIG4.  Finally, 




protein beta 1 (GJB1), which encodes a connexin.  It is the second most prevalent 
form of CMT, affecting 10% of patients9.   
 In this thesis, we exclusively focus on modeling CMT1A.  CMT1A is the most 
common subtype of CMT, affecting an estimated 55% of CMT patients10.  It is 
typically characterized by normal development for the first two decades of life, and 
a subsequent slowly progressive demyelinating and dysmyelinating peripheral 
neuropathy that results in sensory loss, motor deficits, and muscle wasting.  
Physiological studies reveal a slowed nerve conduction velocity, and histological 
analysis demonstrate “onion bulb” formations, indicating repeated rounds of 
demyelination and remyelination.  Therapeutically, CMT1A is treated exclusively 
through orthopedic and surgical interventions, and no targeted pharmacological 
therapies are currently available.   
 The cause of CMT1A is a 1.4 MB duplication in the short arm of chromosome 
17.  This region contains the gene PMP22 (Peripheral Myelin Protein 22), which 
encodes a tetraspan integral membrane glycoprotein found in compact myelin11.  
The myelin sheath is a multi-layered membrane, unique to the nervous system, 
which functions as an insulator to greatly increase the velocity of nerve conduction; 
it is believed that overexpression of PMP22 results in the demyelination and 
dysmyelination seen in CMT1A.  PMP22 is expressed predominantly in Schwann 
cells, but is also expressed in neural crest, neurons, and fibroblasts.  In addition to 
PMP22, the CMT1A duplicated region also contains six known genes, 13 predicted 
genes, at least a dozen long non-coding RNAs, a microRNA, and several 




pathogenesis12 (Figure 3-1B).  In addition, loss of one copy of PMP22 results in 
another neuropathy, Hereditary Neuropathy with Liability to Pressure Palsies 
(HNPP), demonstrating that PMP22 gene dosage must be tightly regulated to 
maintain proper nerve function.   
Based on data from CMT1A patients and animal models, PMP22 is indeed 
believed to be the causative gene in CMT1A pathogenesis.  CMT1A patients, who 
have 3 genomic copies of PMP22, have been shown to overexpress PMP22 mRNA in 
sural nerve biopsy tissue13, Schwann cells cultured from patient sural nervesf14, and 
dermal nerve biopsies15.  Overexpression of PMP22 in rodents leads to a severe 
dys- and demyelinating phenotype, leading to the conclusion that PMP22 
overexpression is sufficient to induce CMT1A pathology.   
 
Rodent models of CMT1A 
In 1996 several independently created CMT1A rodent models were reported.  
The CMT1A transgenic rat, was created through introduction of three additional 
copies of PMP22 to the endogenous genes, leading to five genomic doses total.  The 
CMT1A rat expresses 1.6-fold more PMP22 than controls, and exhibits 
dysmyelination and demyelination in its peripheral and cranial nerves.  Rats display 
an unsteady gait, have “onion bulbs” on histology, and the histological and 
physiological changes precede the motor and sensory phenotypes, similar to CMT1A 




Additionally, several lines of CMT1A transgenic mice were developed 
independently, through overexpression of 4-16 genomic copies of human or murine 
PMP2216–18.  These mice models appear to vary in their ability to recapitulate the 
CMT1A phenotype19.  The TGN248 mouse with 16 copies of the PMP22 transgene 
exhibits severe dysmyelination, yet actually exhibits lower PMP22 mRNA expression 
than controls and lack onion bulbs, making them quite dissimilar from the 
molecular phenotype of CMT1A patients20.   
Around the same time as the CMT1A rat and the TGN248 mouse, the C22 
mouse model of CMT1A was reported by overexpressing seven copies of human 
PMP2216 on a yeast artificial chromosome (YAC).  The resulting mice express 2.7 
fold more PMP22 mRNA, only survive 2-10 months, and demonstrate severe gait 
abnormalities and/or paralysis at 6 months, dys- and demyelination, and basal 
lamina onion bulbs.  They appear to be a more clinically relevant mouse than the 
TGN248 model, yet their PMP22 expression levels, decreased lifespan, and severe 
clinical deficits suggest they might be modeling a more severe disease (ie, perhaps 
Dejerine Sottas Syndrome) than that of most CMT1A patients.  This mouse was 
used for the ascorbic acid trials, as will be discussed shortly.   
Similar to the C22 mouse with seven copies of PMP22, two years later the 
same group reported the C61 mouse created with four additional YAC copies of 
PMP2217.  This mouse exhibits less dramatic PMP22 overexpression than its C22 
counterpart and there is no gross visible motor phenotype.  However, upon 
physiological examination, there is a mild slowing of the motor conduction velocity 




histology some demyelination is visible.  Furthermore, a side-by-side comparison of 
the distribution profile of myelinated and demyelinated nerve fiber sizes closely 
matches that of CMT1A patients21, suggesting the C61 mouse may be the best 
representation of the mild or early clinical phenotype.  This is also the mouse used 
for the Martini groups studies on macrophage infiltration in CMT1A mouse 
nerves22,23, and will be discussed further in Chapter 3.   
Whereas the C22 and C61 CMT1A mice overexpress a human isoform of 
PMP22, two additional mouse models have been created that overexpress the 
mouse isoform of PMP22.  One is the MY41 mouse, made with a mouse YAC, which 
has a severe demyelinating peripheral neuropathy with no evidence of hypertrophy 
or classical onion bulbs21.  Over 70% of axons have no measurable myelin and the 
number of Schwann cells present is three times more than usual.  Another is the 
JP18 mouse, which has a tetracycline-OFF inducible mouse PMP22 YAC transgene24.  
Essentially, PMP22 is constitutively overexpressed in this mouse, and transgene 
expression is switched off by feeding the mouse tetracycline.  In the absence of 
tetracycline, the mice are demyelinated.  However, when PMP22 overexpression is 
switched off in adult mice, remyelination begins to occur within a week and 
myelination is nearly normal with 12 weeks, suggesting that PMP22 overexpression 
is sufficient to cause demyelination in mice. 
 
Comparison of CMT1A rodent models and CMT1A patients 
Overall, it appears that the many rodent models of CMT1A appear to exhibit 




My41 mice being the most severe, perhaps even more severe than what is typical 
clinically.  Unfortunately, none of the models exhibit the mild early phenotype 
observed for the first two decades in humans, followed by a progressive long term 
degeneration characterized by axonal loss and onion bulbs21.  In contrast, other 
than C61, most of the mouse models appear to show a severe demyelinating 
phenotype present from the onset, suggesting they may be better models of the 
more severe end of the CMT1A spectrum, such as Dejerine-Sottas syndrome, rather 
than the average clinical course.  And unfortunately the C61 mouse does not 
develop any long term progressive deficits, even after 18 months21. 
 CMT1A mice also demonstrate a clear dose relationship between PMP22 copy 
number and peripheral nerve deficits, though this same relationship is not as clear 
in humans.  The dose relationship can be seen by comparing the C61 model (4 
copies PMP22), C22 model (7 copies PMP22), and TgN248 (16 copies PMP22); 
increasing the genomic copy number worsens the phenotype dramatically.  It can 
also been seen in the inducible JP18 mouse, where overexpressing PMP22 for 8 
weeks and then switching it off leads to a correction of the myelination deficit. 
However, this relationship between PMP22 gene and protein expression and 
myelination deficits aren’t nearly as clear in CMT1A patients.  Interestingly, CMT1A 
patients appear to exhibit a broader variation in PMP22 protein expression levels 
than normal controls15, and clinical studies demonstrate that levels of PMP22 mRNA 
and protein expression do not correlate significantly with clinical phenotype15.  For 
instance, some patients with high PMP22 expression levels actually experience the 




human form of the disease, such as PMP22 having slightly different functions in 
humans versus rodents, or that factors other than PMP22 may contribute to human 
CMT1A pathogenesis.  An example of factors other than PMP22 that might play such 
a role could be many non-PMP22 genes present in the CMT1A duplicated region 
(Figure 3-1B), none of which are currently included as transgenes in rodent 
models of CMT1A.  Efforts are currently ongoing to identify such potential modifying 
genes using exome sequencing in clinical samples (clinicaltrials.gov Identifier 
NCT01193088). 
Furthermore, another difference between CMT1A rodent models and humans 
is their response to potential pharmacologic treatments.  For instance, it has been 
well established that ascorbic acid is important for Schwann cell basal lamina 
formation and induction of myelination in in vitro settings25,26.  Consequently, trials 
were conducted with C22 CMT1A mice to determine the effect of ascorbic acid 
administration, and it was found to decrease PMP22 expression levels, improve 
locomotion, improve lifespan, and remyelinate the sciatic nerve27,28.  However, 
several follow up clinical trials conducted in both pediatric29,30 and adult 
populations, using both low dose31,32 and high dose33 ascorbic acid treatments, 
unfortunately found little clinical improvement.  This suggests that critical 
differences may exist between rodent models and CMT1A patients, indicating that 
development of novel, more patient-relevant model systems is warranted.   
 In this dissertation, we utilize human CMT1A patient-derived Schwann cells 
to model the disorder and complement existing rodent models.  These human 
Schwann cells come from three different sources: induced pluripotent stem cells, 




fibroblasts that have been directly converted into neural crest and then 
differentiated into Schwann cells.  As human Schwann cells, they should be able to 
1) recapitulate the PMP22-mediated pathology of CMT1A patient Schwann cells, 2) 
reflect the expression or involvement of any non-PMP22 genes in CMT1A 
pathogenesis, and 3) predict response to drugs modulating expression of PMP22 
and other mediators of CMT1A. 
 
Immunocompetence of Schwann cells 
Over the course of this study, a phenotype of inflammatory dysregulation 
was found in the CMT1A Schwann cells.  Because Schwann cells are not classically 
considered effectors of the immune system, here we briefly review the 
immunocompetence of Schwann cells, much of which has been previously described 
by Patricia J. Armati in The Biology of Schwann Cells: Development, Differentiation, 
and Immunomodulation.   
Whereas the nervous system has long been considered an immune privileged 
location, there is substantial evidence to the contrary.  Immune privilege is the idea 
that there are certain regions, the nervous system, cornea, retina, anterior 
chamber of the eye, testis, and liver for example, in which immune surveillance is 
reduced34.  The idea originated in 1948 from Medagar’s observations that 
homologous skin transplantations into the brain did not elicit the same degree of 
immune response as transplantations into other sites35.  The theory was based on 
the idea that there is 1) anatomic separation between blood and neural tissue, 2) 




conditions, 3) absence of lymph drainage, and 4) decreased T-cell 
surveillance34,36,37.  While the blood nerve barrier does limit immune cell access to a 
certain degree, it is far from impermeable, particularly at anatomic sites like nerve 
roots, nerve ganglia, and motor terminals.  In addition, recent work has 
demonstrated that Schwann cells can participate in a wide spectrum of immune 
activities including: antigen recognition, antigen presentation, and immune 
response generation36.   
Antigen recognition by Schwann cells is evidenced by their expression of Toll-
like receptors, which are “pattern-recognition receptors” that recognize 
stereotypical pathogen-associated structures; their recognition plays an important 
role in the acute response of the innate immune system.  Evidence for Schwann cell 
participation in antigen recognition comes from Schwann cell expression of toll-like 
receptors 2, 3, and 4, and suggests they may even act as sentinel cells for the 
PNS38,39.  In addition to potential pathogens, necrotic neuronal cells can also 
activate Toll-like receptors of Schwann cells and cause pro-inflammatory cytokine 
secretion, suggesting a role for Schwann cells TLR-signaling in mediating peripheral 
nerve injury40.  Another study demonstrated that TLR-signaling is essential for 
macrophage recruitment and myelin debris clearance during Wallerian 
degeneration41. 
Antigen presentation by Schwann cells is supported by their constitutive 
expression of MHC class I molecules and inflammation-induced expression of MHC 
class II molecules42.  All nucleated cells can present MHC class I molecules to CD8+ 




class II molecules.  MHC class II molecules display antigen peptides to CD4+ T-
cells, and if there is a second co-stimulatory molecule, the T cell will become 
activated and mount an immune response.  Pollard, et al, found that Schwann cells 
stained positive for MHC class II molecules in patients with chronic inflammatory 
demyelinating polyneuropathy (CIDP) and Guillain-Barre syndrome (GBS), 
suggesting that Schwann cells may indeed act as antigen presenting cells in 
inflammatory PNS disorders43,44.  In addition, it’s also been found that Schwann 
cells of CIDP patients express the co-stimulatory molecule BB-1, meaning they 
have all the molecular components to act as antigen presenting cells45.  Although 
successful antigen presentation to T-cells has been demonstrated in vitro, the 
extent to which Schwann cells actually play a meaningful role in antigen 
presentation in vivo is still controversial46,47. 
Generation of an immune response by Schwann cells, on the other hand, is 
no longer controversial.  At one point it was believed that only immune cells in the 
nervous system could release cytokines, but now there is ample evidence that 
Schwann cells, microglia, astrocytes, and oligodendrocytes can all secrete cytokines 
upon appropriate stimulation47.  Schwann cells have been shown to secrete a 
myriad of cytokines in various physiological and pathological conditions, including, 
but not limited to: IL-1, which initiates T-cell mediated immune responses48,49; IL-
6, which is a monocyte chemoattractant50; TNF-α, which mediates multiple 
proinflammatory functions and can also induce cell death, proliferation, and 
differentiation51,52; and TGF-β, which is a master regulator of inflammation and cell 
proliferation53.   Whether the effects of such cytokine release by Schwann cells are 




during Wallerian degeneration, upregulation of MCP-1, Mip1-a, and IL1-B and the 
subsequent recruitment of macrophage actually facilitates clearance of myelin and 
axonal debris, thus creating a more permissive environment for axon 
regeneration54,55.   
In addition to secreting cytokines, Schwann cells also have some of the 
physical capabilities of immune effectors, such as phagocytosing myelin themselves 
as has been demonstrated by several studies of Wallerian degeneration.  It appears 
that in early response to axotomy, Schwann cells de-differentiate and begin 
reabsorbing the lipid myelin debris, as the segmented myelin sheath and axonal 
debris can be seen within Schwann cell cytoplasmic vacuoles56–58.  Subsequently, 
macrophages are recruited to the lesion and perform the bulk of myelin 
phagocytosis, but it is the Schwann cells that initiate the process. 
Relative to their role in synthesizing myelin, Schwann cell functions in 
immune surveillance and immune modulation has been comparatively 
underappreciated.  Engineered Schwann cells, such as those developed in Chapter 
2, may very well model the immunomodulatory functions of endogenous Schwann 








CHAPTER 2: DIRECTED DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS 







Schwann cells are the myelinating glia of the peripheral nervous system.  
Their synthesis of myelin allows peripheral nerves to conduct sensory and motor 
signal with rapid efficiency and fidelity.  Developmentally, they originate from 
neural crest, which delaminate from the neural tube and migrate extensively to give 
rise to a number of different cell types throughout the body.  They include Schwann 
cells, sensory neurons, autonomic neurons, enteric neurons, and melanocytes, as 
well as bones, cartilage and connective tissue in the craniofacial region. 
During development, Schwann cells and sensory neurons form in parallel.  
Through a process of radial sorting, each Schwann cell selectively associates with 
one neuron and forms a single segment of compact myelin.  Disrupting this 
peripheral myelin results in numbness, tingling, difficulty moving, and often 
debilitating disability, as evidenced by disorders like Charcot Marie Tooth disease, 
Hereditary Neuropathy with Liability to Pressure Palsies, Guillain-Barre Syndrome, 
and chronic inflammatory demyelinating polyradiculopathy.   
 Our current understanding of these disorders is far from complete and our 
current treatment options leave patients much to be desired.  Studying Schwann 
cell disorders directly through patient biopsies, while perhaps scientifically ideal, is 
ethically and clinically challenging as it would remove an intact nerve from a patient 
who has limited nerve function.  Consequently, animal models are extensively used 
to model these disorders, study their pathology, and screen for therapeutics to 
reverse that pathology.  These animal models, while extremely valuable as an in 




models, they may not fully recapitulate the human pathophysiology, and drugs that 
might prove efficacious in humans may not pass screening trials in rodents, and 
vice versa.   
 This is where engineering human stem cells towards the Schwann cell lineage 
might prove useful.  Human pluripotent stem cell technology allows us to create 
potentially unlimited numbers of any target cell type.  Developing Schwann cells 
from human embryonic and induced pluripotent stem cells would allow us to better 
model Schwann cell disorders, perform high throughput drug screens in disease 
relevant cells types, and offer a source of potentially clinically transplantable 
Schwann cells. 
 By taking advantage of our lab’s prior experience with human pluripotent 
stem cell differentiation into neural crest and its sublineages, we were able to 
develop a protocol for the derivation of Schwann cells from hPSCs.  Although a few 
other such protocols have already been published (one for hPSC differentiation 
towards Schwann cells6; one for fibroblast conversion to Schwann cells59), we 
believe that our method offers several advantages.  Ours uses a chemically defined 
method and 2D monolayer culture method to provide precise control over cell fate.  
It also features a FACS purification method to selectively isolate and replate 
Schwann cells in the absence of contaminating cell types.  We believe that the 
resulting human Schwann cells provide an effective and impactful platform for 






SOX10 and OCT4 hESC reporter line generation 
The human embryonic stem cell line, H9 (also known as WA09) was modified to 
express eGFP under the SOX10 or OCT4 promoter, using the TALEN genome editing 
system, as previously described by published methods60,61.  Briefly, feeder-free H9 
hESCs were dissociated into single cells using Accutase and 2 × 106cells were 
resuspended in nucleofection solution V (Lonza) with 12 μg total plasmids and 
nucleofected by Nucleofector™ II according to manufacturer’s instructions (using B-
16 program, Lonza). The nucleofected cell suspension were subsequently plated on 
the puromycin-resistant MEFs (DR4, Global Stem) in hESC media with 10 μM Y-
27632. Four days after nucleofection, cells that have undergone homologous 
recombination were selected adding 0.5 μg/ml of puromycin in the hESC media. To 
verify the chromosomal aberrations, karyotype analyses were performed on the 
candidate clones (Cell Line Genetics, Inc.). 
These lines were generated by Ho Tae Lim and Yohan Oh, both members of the Lee 
Lab. 
 
Schwann cell differentiation 
H9 Sox10::eGFP cells were plated and differentiated into putative Schwann cells, as 
described extensively in Appendix 1.  Briefly, colonies of pluripotent cells were 




like matrix.  They were then treated with a combination of small molecules to 
induce neuronal and Schwann cell differentiation: 
1. To initiate differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542 and 500 nM LDN-193189 (day 0).   
2. On day 2 of differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542, 500 nM LDN-193189, 3 µM CHIR 99021, 10 
µM DAPT.   
3. On day 4 of differentiation, aspirate the medium and add KSR/NB (3:1) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT (final 
concentrations are for the combined KSR/NB mixture). 
4. On day 6 of differentiation, aspirate the medium and add KSR/NB (1:1) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT. 
5. On day 8 of differentiation, aspirate the medium and add KSR/NB (1:3) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT.  
6. On day 10 of differentiation, aspirate the KSR/NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
7. On day 14 of differentiation, aspirate the NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
8. On day 18 of differentiation, aspirate the NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
9. Maintain in this manner until day 21-23 of differentiation, when the cells 
are ready for purification. 
 




The FACS protocol is described extensively in Appendix 1.  Briefly, Schwann cells 
were purified with Fluorescence Activated Cell Sorting (FACS) after 21-23 days of 
differentiation using a PE-conjugated antibody to the alpha4 integrin, CD49d (R&D 
Systems, FAB1354P).  After FACS, Schwann cells were replated onto tissue culture 
plates treated with fibronectin (R&D Systems, 1918-FN-02M) and laminin (Cultrex, 
R&D Systems, 3400-010-1) coated plates.  (Plates were coated with 1ug/mL 
laminin and 2ug/mL fibronectin in PBS for 24 hours).  Cells were maintained in 
culture for up to 80 days post-FACS using Neurobasal medium (Life Technologies, 
21103-049) supplemented with L-glutamine (Life Technologies, 25030-081), B-27 
supplement (Life Technologies, 12587-070), N2 supplement (Life Technologies, cat. 
no. 17502-048), and 1% fetal bovine serum (Hyclone, cat. no. SH30070.03). 
 
OCT4+ embryonic stem cell purification 
H9 OCT4::eGFP human embryonic stem cells were maintained clonally and 
OCT4::eGFP positive pluripotent cells were FACS purified.  This step was performed 
by Yohan Oh, a postdoctoral fellow in the Lee lab. 
 
SOX10+ Neural crest generation and purification 
H9 SOX10::eGFP cells were plated and as described above for Schwann cell 
differentiation.  For differentiation towards neural crest: 
1. To initiate differentiation, aspirate the medium and add KSR medium 




2. On day 2 of differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542, 500 nM LDN-193189, 3 µM CHIR 99021. 
3. On day 3 of differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542, 3 µM CHIR 99021. 
4. On day 4 of differentiation, aspirate the medium and add KSR/NB (3:1) 
medium containing 3 µM CHIR 99021 (final concentrations are for the 
combined KSR/NB mixture). 
5. On day 6.5 of differentiation, Sox10::eGFP positive neural crest were FACS 
purified. 
This step was performed by Yohan Oh, a postdoctoral fellow in the Lee lab. 
 
Immunofluorescence 
Cells were fixed in 4% Paraformaldehyde for 20 minutes, then blocked and 
permeablized in 0.5%BSA and 0.1% Triton X-100 in PBS for 30 minutes.   Primary 
antibodies were diluted 1:100 to 1:500 in 0.5%BSA and 0.1% Triton X-100 in PBS 
and samples were incubated overnight at 4 degrees.  Secondary antibodies were 
diluted 1:1000 in 0.5%BSA and 0.1% Triton X-100 in PBS, and incubated 2 hours 
at room temperature.  Primary antibodies can be found in Appendix 2.  Appropriate 
488, 568, and 647-conjugated Alexa fluor secondary antibodies were utilized.  
 
RNA extraction, real time PCR, and microarray analysis 
Cells were homogenized in Trizol Reagent (Life Technologies, 15596-026) and 




reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, 4387406).  Real time PCR was performed on an Eppendorf 
Realplex Mastercycler Ep gradient S.  Cycling conditions are as follows: 95 degrees 
2 min, 40 cycles (95 degrees 3 seconds, 60 degrees 30 seconds).  Primer probes 
can be found in Appendix 2.  For microarray analysis, total RNA from Oct4+ 
embryonic stem cells, Sox10+ neural crest, and CD49d+ Schwann cells were 
hybridized in triplicate to the Affymetrix Primeview Human Gene Expression Array 
by the Johns Hopkins Deep Sequencing and Microarray Core.  Data analysis and 
visualizations were performed in Partek and Spotfire.  Transcripts that were up- and 
down-regulated 2-fold with a p-value greater than 0.05 were further analyzed using 





LSB2i treatment for 21-23 days yields Sox10+ Schwann cells and Tuj1+ neurons 
We plated human embryonic stem cells modified to report eGFP under the 
SOX10 promoter (H9 SOX10::eGFP cells).  The H9 human embryonic stem cell line, 
one of the original human embryonic stem cell lines first developed by Jamie 
Thompson62, was chosen as it’s one of the most extensively utilized and best 
characterized human ES lines available63.  Furthermore, its ability to be 
differentiated towards neuroectodermal lineages has been well established64–66.   
We found that by modifying a published protocol (referred to as the LSB3i 
protocol, Fig. 2-1B) for sensory neuron differentiation67, we were able to enhance 
Schwann cell differentiation.  The LSB3i sensory neuron differentiation protocol 
consists of 10 days of treatment with five small molecules.  Treatment from Day 0 
to Day 4 with two such small molecules (LDN-1931189 and SB431542, collectively 
referred to as LSB) effectively neuralize the fate of the H9 cells by inhibiting the 
SMAD/TGFbeta pathway68.  Treatment from Day 2 to Day 10 with three additional 
small molecules (DAPT, CHIR99021, and SU5402, called 3i for ‘three inhibitors’) 
serves to differentiate the cells into neurons of dorsal root ganglia, as opposed to 
CNS neurons.  Specifically, DAPT is a γ-secretase inhibitor that blocks Notch 
signaling, also neuralizing the fate of the cells.  CHIR99021 is a WNT agonist that 
inhibits glycogen synthase kinase-3β (GSK-3β) and stabilizes β-catenin, and 
thereby promotes a neural crest cell fate (as opposed to a CNS/neural tube fate).  




factor (FGF) and platelet-derived growth factor (PDGF) tyrosine kinase signaling 
pathways67, and serves to increase the efficiency of neuron generation.  
We modified this LSB3i protocol to create a new protocol (dubbed LSB2i, Fig. 
2-1C) that is optimized for Schwann cell generation.  We eliminated the use of 
SU5402 in order to decrease the efficiency of neuronal specification, as we wanted 
to maximize glial specification.  After 10 days of treatment with LDN-1931189, 
SB431542, DAPT, and CHIR99021, we treat the cells for an additional 11-13 days 
with cAMP and ascorbic acid, to promote Schwann cell proliferation69–72 and 
maturation73,74.  After a total of 21-23 days of differentiation, a mixed population of 
cells results (Fig. 2-2A) and SOX10::eGFP+ Schwann cells can be seen in close 
association with TUJ1+ neurons.   
CD49d-PE can be used to prospectively isolate Schwann cells 
As the differentiation protocol yields a mixture of Schwann cells, neurons, 
and non-neuronal cell types, it is important to be able to purify the Schwann cell 
population.  Towards this end, we have utilized CD49d as a cell surface marker that 
can be utilized to purify the Schwann cell population.  The protein CD49d is an 
alpha4 integrin previously identified to be expressed on the surface of Schwann cell 
precursors4, the earliest member of the Schwann cell lineage.  By FACS purifying 
differentiated H9 SOX10::eGFP cells for CD49d-PE, we could isolate a CD49d+ 
putative Schwann cell population and CD49d- putative non-Schwann cell 
population.  As expected, the CD49d+ population also expresses a high level of 
eGFP (Fig. 2-2B), demonstrating that the SOX10 promoter is highly active in these 




precursors.  Furthermore, the average yield of CD49d+ cells from the H9 hESC line, 
as determined during FACS purification, is 13.62% (n=27) (Fig. 2-2C).   
Schwann cell lineage genes are enriched in the CD49d+ population and 
downregulated in the CD49d- population 
To further characterize these CD49d+ putative Schwann cells, we used 
qRTPCR to evaluate Schwann cell gene expression in the CD49d+ fraction, CD49d- 
fraction, and in unsorted cells. Real time PCR was performed for SOX10 (expressed 
on neural crest, Schwann cell precursors, and immature Schwann cells), Dessert 
Hedgehog (DHH) (expressed on Schwann cell precursors and immature Schwann 
cells), and Cadherin19 (CDH19) (specific to Schwann cell precursors)4,75 (Fig. 2-
2D).  Results demonstrate that these three Schwann cell genes are specifically 
enriched in the CD49d+ population, and are downregulated in the CD49d- 
population, relative to the unsorted population.  This suggests that our protocol 
yields a cellular population that expresses Schwann cell marker genes, specifically 
of the Schwann cell precursor sublineage. 
OCT4+ hESCs, SOX10+ neural crest, and CD49d+ Schwann cells have distinct gene 
expression profiles and upregulate Schwann cell signaling pathway genes 
  Whereas the data thus far demonstrates an enrichment of Schwann cell 
precursor gene expression in CD49d+ cells relative to CD49d- and unsorted LSB2i 
treated cells, here we investigate enrichment of Schwann cell genes relative to 
independently generated, developmentally relevant cell populations.  Towards this 
end, we compared the global gene expression profile of CD49d+ cells against 




embryonic stem cells.  The human embryonic stem cells were obtained by taking 
H9 OCT4::eGFP cells and FACS-purifying the eGFP+ population.  Because the OCT4 
promoter is critical for the maintenance of pluripotency, this method will yield only 
pluripotent stem cells.  The neural crest were obtained from H9 SOX10::eGFP cells 
that were differentiated in vitro towards the neural crest lineage, and then FACS 
selected for the SOX10::eGFP+ neural crest population.  Microarray profiling of 
human embryonic stem cells, neural crest, and CD49d+ putative Schwann cells 
reveals that the three populations have quite different gene expression profiles, as 
evident from the heat map representation of the data (Fig. 2-3A).  Hierarchical 
clustering and the resulting dendrogram profile demonstrates that the three 
populations are quite distinct and, as expected, the neural crest and CD49d+ 
putative Schwann cell populations are more similar to each other than they are to 
the human ES cells.   
 Gene ontology and pathway analysis of the genes differentially expressed 
between the CD49d+ putative Schwann cell population and the OCT4+ hESCs found 
significant representation of pathways and categories critical for gliogenesis and 
Schwann cell development, including Erbb signaling (p=0.0000758), Neuregulin 
signaling (p=0.000436), Gliogenesis (p=0.000430), PDGF signaling (p=0.0120), 
and CNTF signaling (p=0.0370) (Fig. 2-3B).  This suggests that these Schwann cell 
development pathways are indeed activated in the CD49d+ cells, further supporting 
the idea that they are Schwann cells. 
Both classical and non-classical Schwann cell lineage genes are highly upregulated 




Among the most highly upregulated genes in the CD49d+ population is 
S100B, a well-established Schwann cell marker4, and less classically, these cells 
also robustly express GPR126 and POSTN (Periostin), all of which were confirmed 
by qRTPCR (Fig. 2-4A).  GPR126 encodes a G-protein coupled receptor which has 
been shown to be essential for initiation of myelination76–78.  POSTN (Periostin) 
encodes an adhesive glycoprotein that facilitates the migration of cells undergoing 
epithelial to mesenchymal transition during development; it expressed in Schwann 
cells in addition to endocardial cushions79. 
FACS-purified cultured CD49d+ cells exhibit bipolar morphology and express 
classical Schwann cell proteins 
 All of the above studies were performed on FACS purified CD49d+ Schwann 
cells.  After FACS the cells can also be replated and cultured for up to 80 days in 
NB+1%FBS.  After 20+ days post-FACS, the cells exhibit an elongated morphology 
stereotypical of Schwann cells and immunostain positively for several classical 
Schwann cell protein markers such as S100b, GFAP, and GalC (Fig. 2-4B), 
providing further evidence that they are indeed Schwann cells and also 
demonstrating the CD49d+ population’s ability to mature in vitro. 
Statistical analyses 
Data was analyzed using Graphpad Prism 6.  Means +/- standard deviation are 
plotted, and p-values were calculated using the unpaired t test, ratio paired t test, 
















Figure 2-1.  A. Schematic of LSB2i differentiation.  B. Previously 
published LSB3i small molecule treatment timeline for sensory neuron 
generation.  C. LSB2i small molecule treatment timeline for Schwann 













Figure 2-2.  A. Immunofluorescence for eGFP and TUJ1 demonstrate 
SOX10+ Schwann cells in association with TUJ1+ neurons (bar = 50 μm).  
B. Flow cytometry demonstrates substantial overlap between the CD49d+ 
population and Sox10::eGFP expression.  C. FACS purification of LSB2i 
treated control H9 hESCs. Each dot represents an independent 
differentiation (n=27). Data expressed as mean +/-SD.  D. Real time PCR 
for Schwann cell lineage markers in CD49d+ putative Schwann cells, 
CD49d- non-Schwann cells, and unsorted cells. Data expressed as mean 
+/- SD (standard deviation), n = 5 for each cell type, p-values calculated 





Figure 2-3: Global gene expression profiling of ES, NC, and CD49d+ 









Figure 2-3.  A. Heat map representation of supervised hierarchical 
clustering of Oct4::eGFP+ hESCs, Sox10::eGFP+ neural crest, and 
CD49d+ putative Schwann cells, based on all differentially expressed 
genes with p<0.001. B. Gene ontology and pathway analysis of genes 





Figure 2-4: Microarray validation and post-FACS purification plating and 








Figure 2-4.  A. Validation of microarray results with qRTPCR for select 
Schwann cell genes, normalized to GAPDH. n = 3 differentiations for each 
cell type. Data expressed as mean +/- SD; p-values calculated by one-way 
ANOVA. * p<0.05, *** p<0.001.  B. Post-FACS purified CD49d+ cells may 
be replated and cultured up to 80 days. Representative 








Here we demonstrate the in vitro derivation of human Schwann cells from 
human embryonic stem cells.  In contrast with previously published protocols, this 
protocol utilizes a monolayer culture method (as opposed to spheres), features 
defined conditions, and includes a FACS-based purification method, with replating 
possible.  Replating is significant as it enables further study of cell autonomous 
phenotypes and may also allow for in vitro maturation of the Schwann cell 
precursors along the Schwann cell lineage.    
When developing any protocol for human embryonic stem cell differentiation 
towards a target cell type, several different factors must be taken into consideration 
to develop an ideal protocol.  One major issue is whether the protocol will utilize 3 
dimensional (3D) spherical structures (ie embryoid bodies and neurospheres) or a 
two dimentional (2D) adherent monolayer culture.  Whereas the use of 3D 
structures is well established and perhaps better models the 3D environment in 
which development occurs in vivo, many believe that 2D monolayer cultures 
provide the operator superior control over the fate of the cells68,80.  This is because 
each cell plated in a 2D culture is exposed to the differentiation medium fairly 
equally, whereas in 3D cultures, each cell is receiving quite varied environmental 
and differentiation signals based on its location within the embryoid body or 
neurosphere.  Our Schwann cell derivation protocol uses the 2D monolayer method 
based on the well-adopted dual-SMAD inhibition method of neuronal differentiation, 
resulting in cleaner, more precise control over their fate specification68. 
Another determination that needs to be made when designing a stem cell 




molecular cues to pattern the fate of the cells.  Generally these sources can fall into 
two categories: “not defined” and “defined.”  “Not defined” tissue culture conditions 
include animal-derived serums and matrix products that may vary substantially 
from lot to lot and whose constituent components are poorly understood.  They can 
also include proprietary formulations whose contents are not readily ascertainable.  
“Defined” tissue culture conditions on the other hand consist of known small 
molecules, recombinant proteins, and lack animal products.  The use of defined 
conditions in stem cell research is significant for several reasons, and is being 
increasingly adopted for both hESC maintenance81–84 and differentiation85,86.  First 
of all, particularly in developmental studies, it is valuable to know exactly what 
molecular cues are patterning the fate of the cells.  Second of all, reproducibility is 
important in stem cell engineering, and batch variation of animal products could 
result in large variability in stem cell differentiation towards the target cell type.  
Third of all, exposure to animal products may also induce undesired immunogenic 
responses in the stem cells87, which bodes poorly for their potential transplantation 
in clinical settings.  Finally, using defined conditions also makes the resulting cells 
readily transferable to a Good Manufacturing Practices facility for future clinical 
applications.  Our protocol uses defined conditions during differentiation until FACS 
purification.  After FACS, the cells are plated in Neurobasal medium + 1% fetal 
bovine serum, a non-defined condition due to the presence of serum.  Much effort 
was made to find a defined condition for culture of the cells after FACS, and while 
the cells could survive in Neurobasal + FGF2 + EGF (data not shown), they did not 




protocol can potentially be adapted to clinical applications if utilized immediately 
upon FACS purification.   
The cells yielded by our defined LSB2i protocol exhibit the morphological, 
genetic, and protein signatures of Schwann cells, which we interpret to mean they 
are indeed Schwann cells.  However, it should be noted that the ability of these 
cells to myelinate, perhaps the best known function of Schwann cells, has yet to be 
demonstrated.  Coculture experiments with human ES-derived motor neurons were 
attempted, without any evidence of myelination.  Coculture experiments with rat 
dorsal root ganglion neurons, in combination with forced overexpression of 
transcription factors promoting myelination (ie Oct6, Krox20), are in progress.  
Unfortunately human Schwann cells are extremely difficult to force to myelinate, 
particularly compared to rodent Schwann cells and oligodendrocytes.  First of all, 
human primary Schwann cells are not nearly as extensively studied ex vivo as 
rodent primary Schwann cells, due to the ethical and technical barriers in obtaining 
such clinical samples, meaning conditions promoting Schwann cell myelination are 
also less studied in humans than rodents.  During studies of human Schwann cell 
myelination, species barriers between the human Schwann cells and typically 
rodent substrate neurons may very well limit myelination efficiency88.  Additionally, 
human ESC-derived Schwann cells may also be less developmentally mature than 
primary Schwann cells, which provides another barrier to myelination.  Even though 
other groups have published Schwann cell differentiation protocols, it is clear that 
demonstrating their myelination potential has been challenging.  In one study on 
hESC and hiPSC differentiation to Schwann cells the efficiency was low, as 




Schwann cell generation via direct lineage conversion from fibroblasts, they also 
reported low efficiency, and also did not perform a critical experiment that would 
rule out myelination from rodent Schwann cells contaminating their rat DRG-human 
Schwann cell coculture59.  Our difficulty experienced in human ESC-derived 
Schwann cell myelination is in line with what has been reported in the literature88. 
Even in the absence of myelination data, our human ESC-derived Schwann 
cells still have many potential applications.  Because they express all the molecular 
characteristics of Schwann cells, they are likely useful for modeling the molecular 
pathology of Schwann cell disorders, particularly hereditary ones.  The 
pathophysiology of most Schwann cell disorders are currently best understood 
through rodent models, but there can be limitations in extrapolating rodent model 
data to human patients.  As a source of human Schwann cells, they can provide 
human-specific, and if using hiPS cells, individual patient-specific data that would 
otherwise be unobtainable using other model systems. 
Additionally, these human pluripotent stem cell (hPSC)-derived Schwann 
cells can also be used for drug screening in a number of different contexts.  Control 
hPSC-derived Schwann cells could be screened for drug doses that minimize toxicity 
to Schwann cells, which might be useful when developing or dosing potentially 
neurotoxic drugs.  Furthermore, “diseased” hPSCs could be developed that harbor 
the genetic mutation that causes a Schwann cell disorder.  Such disease Schwann 
cells could also be screened for drugs that alleviate the effects of the genetic 




gene, high-throughput drug screening could be performed for agents that restore 
transcription to normal levels.   
Given further advances in the clinical and regulatory arenas, our hPSC-
derived Schwann cells could potentially be adapted to clinical transplantation 
studies.  Due to the prevalence of hereditary and acquired Schwann cell disorders, 
hPSC-derived Schwann cell replacement therapy is an exciting possibility.  Other 
potential therapeutic applications of these cells include Schwann cell-mediated 
spinal cord remyelination in spinal cord injury89, central nervous system 







 We have developed a defined protocol for the direct derivation and 
prospective isolation of Schwann cells from human embryonic and induced 
pluripotent stem cells.  Potential uses of these cells include disease modeling, drug 
screening, and transplantation therapy, making them an exciting platform for 






CHAPTER 3: MODELING CHARCOT MARIE TOOTH 1A WITH INDUCED PLURIPOTENT 






In chapter 2, we established a protocol for derivation of Schwann cells from 
human embryonic stem cells.  Potential uses of these cells include disease 
modeling, drug screening, and transplantation therapy.  Here were report the use 
of our Schwann cell derivation protocol from chapter 2 to model the hereditary 
Schwann cell disorder, Charcot Marie Tooth 1A.  
Given the similarities between human embryonic stem cells (hESCs) and 
human induced pluripotent stem cells (hiPSCs), as human pluripotent stem cells, 
our hESC-based Schwann cell differentiation protocol should readily be adapted to 
human iPSCs94.  While hESCs can be used for disease modeling by introducing the 
causative genetic mutation into the hESC line, in many regards, hiPSCs provide a 
superior platform for disease modeling.  hiPSCs are generated by epigenetically 
reprogramming a patient’s somatic cells (ie skin fibroblasts) to a pluripotent state 
and are genomically identical to the patient’s cells.  Consequently hiPSCs can offer 
a disease modeling platform that 1) doesn’t require any genetic manipulation, 2) is 
patient-specific, and 3) can better represent the genetic variability present in 
patients.   
As reviewed in Chapter 1, there are many genetic Schwann cell disorders 
that might potentially benefit from disease modeling with hiPSCs, including 
numerous CMT1 subtypes, Hereditary Neuropathy with Liability to Pressure Palsies 
(HNPP), Dejerine-Sottas disease, schwannomatosis, vestibular schwannomas of 
Neurofibromatosis Type II (NF2), and perhaps Refsum’s disease. Several 




cell differentiation platform.  First of all, there is only one major cell type believed 
to be implicated in CMT1A (the Schwann cell), as opposed to other disorders like 
NF2 which likely involve multiple cell types and add a layer of complexity to disease 
modeling.  Second of all, the CMT1A duplication appears to vary less from patient 
to patient compared to mutations causing some of the other Schwann cell 
disorders.  (It should be noted that some cases of CMT1A can be caused by a point 
mutation in PMP22, and those patients were not included in our study.)  HNPP, on 
the other hand, can be caused by either a deletion or a frameshift mutation 
resulting in premature stop codon, and such genetic heterogeneity would add 
additional complexity to our analysis.  Additionally, the pathophysiology of how the 
CMT1A duplication results the clinical symptoms is not well understood, resulting in 
a fair amount of clinical need.  Finally, as CMT1A is the most prevalent genetic PNS 
disorder, any new knowledge generated by CMT1A modeling with hiPSCs may also 
have the broadest impact.  
Here we use skin biopsies from three different clinically affected CMT1A 
patients (a father, his daughter, and one unrelated individual) to generate CMT1a 
hiPSCs, differentiate them into Schwann cells, perform gene expression profiling, 






CMT1a human induced pluripotent stem cell line generation 
Fibroblasts from three CMT1A patients were obtained from the Coriell Biorepository 
(GM05148, GM05165, GM05167).  In accordance with previously published 
protocols95, fibroblasts were reprogrammed into induced pluripotent stem cells 
using the Cytotune Sendai Reprogramming Kit (LifeTech A1378001).  After 2 weeks 
of reprogramming, hiPSCs were identified by their colony morphology and replated 
onto mouse embryonic fibroblast (MEF) feeder layers.  They were maintained on 
MEF feeder layers through weekly passaging for up to 50 passages. 
Schwann cell differentiation from CMT1A hiPSC lines 
CMT1A and control hiPSCs were plated and differentiated into putative Schwann 
cells, as described extensively in Appendix 1.  Briefly, colonies of pluripotent cells 
were rendered into single cells and plated on Geltrex, an artificial basement 
membrane-like matrix.  They were then treated with a combination of small 
molecules to induce neuronal and Schwann cell differentiation: 
1. To initiate differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542 and 500 nM LDN-193189 (day 0).   
2. On day 2 of differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542, 500 nM LDN-193189, 3 µM CHIR 99021, 10 
µM DAPT.  (activates WNT while blocking gamma secretase/Notch) 
3. On day 4 of differentiation, aspirate the medium and add KSR/NB (3:1) 




concentrations are for the combined KSR/NB mixture). 
4. On day 6 of differentiation, aspirate the medium and add KSR/NB (1:1) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT. 
5. On day 8 of differentiation, aspirate the medium and add KSR/NB (1:3) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT. Some toxicity may 
be observed that is inversely correlated with efficiency of SOX10 induction. 
6. On day 10 of differentiation, aspirate the KSR/NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
7. On day 14 of differentiation, aspirate the NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
8. On day 18 of differentiation, aspirate the NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
9. Maintain in this manner until day 21-23 of differentiation, when the cells 
are ready for purification. 
 
CMT1A hiPSC-derived Schwann cell purification and culture 
The FACS protocol is described extensively in Appendix 1.  Briefly, Schwann cells 
were purified with Fluorescence Activated Cell Sorting (FACS) after 21-23 days of 
differentiation using a PE-conjugated antibody to the alpha4 integrin, CD49d (R&D 
Systems, FAB1354P).  After FACS, Schwann cells were replated onto tissue culture 
plates treated with fibronectin (R&D Systems, 1918-FN-02M) and laminin (Cultrex, 
R&D Systems, 3400-010-1) coated plates.  (Plates were coated with 1ug/mL 




culture for up to 80 days post-FACS using Neurobasal medium (Life Technologies, 
21103-049) supplemented with L-glutamine (Life Technologies, 25030-081), B-27 
supplement (Life Technologies, 12587-070), N2 supplement (Life Technologies, cat. 
no. 17502-048), and 1% fetal bovine serium (Hyclone, cat. no. SH30070.03). 
Immunofluorescence 
Cells were fixed in 4% Paraformaldehyde for 20 minutes, then blocked and 
permeablized in 0.5%BSA and 0.1% Triton X-100 in PBS for 30 minutes.   Primary 
antibodies were diluted 1:100 to 1:500 in 0.5%BSA and 0.1% Triton X-100 in PBS 
and samples were incubated overnight at 4 degrees.  Secondary antibodies were 
diluted 1:1000 in 0.5%BSA and 0.1% Triton X-100 in PBS, and incubated 2 hours 
at room temperature.  Primary antibodies can be found in Appendix 2.  Appropriate 
488, 568, and 647-conjugated Alexa fluor secondary antibodies were utilized.  
RNA extraction, real time PCR, and microarray analysis 
Cells were homogenized in Trizol Reagent (Life Technologies, 15596-026) and 
manufacturer’s protocols were followed to extract total RNA.  0.5 ug total RNA was 
reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, 4387406).  Real time PCR was performed on an Eppendorf 
Realplex Mastercycler Ep gradient S.  Cycling conditions are as follows: 95 degrees 
2 min, 40 cycles (95 degrees 3 seconds, 60 degrees 30 seconds).  Primer probes 
can be found in Appendix 2.  Data from real time PCR for microarray validation 
probes in were displayed as fold change in CMT1A sample expression versus 
median gene expression in controls, and analyzed with the ratio paired t-test.  Four 




Affymetrix Primeview Human Gene Expression Array by the Johns Hopkins Deep 
Sequencing and Microarray Core.  Data was analyzed and visualized using Partek 
and Spotfire software.  Pathway analysis was performed with Ingenuity Pathway 
Analysis on genes up- and downregulated at least 3 standard deviations from the 
mean (corresponding to a fold change of 2.9 in CMT1A samples vs controls), and 
Gene Ontology analysis was performed with DAVID on genes upregulated at least 3 
standard deviations from the mean. 
Cytokine expression profiling 
Upon FACS purification, matched pairs of CMT1A and control hiPSC-Schwann cells 
with at least 1.5-fold upregulation of PMP22 transcript were identified.  FACS 
purified CD49d+ Schwann cells were maintained in culture for 10 days post-FACS.  
Cell conditioned medium was profiled with the Human Cytokine Array Kit (R&D 
Systems, ARY005) according to manufacturer’s instructions, and fold change in 
expression of a given protein in CMT1A hiPSC-Schwann cells versus control hiPSC-
Schwann cells were reported. 
Statistical analyses 
Data was analyzed using Graphpad Prism 6.  Means +/- standard deviation are 
plotted, and p-values were calculated using the unpaired t test, ratio paired t test, 





CMT1A patient fibroblasts may be successfully reprogrammed into induced 
pluripotent stem cells  
Here we report the successful generation of CMT1A hiPSCs and their 
subsequent differentiation into Schwann cells (Fig. 3-1A).  We obtained skin 
fibroblasts from three different CMT1a patients from the Coriell biorepository: a 
father (51 year old Caucasian male), his daughter (a 28 year old Caucasian 
female), and an unrelated CMT1A patient (17 year old Caucasian male).  Using 
multiplex ligation dependent probe amplification (MLPA), Coriell had confirmed the 
presence of the PMP22 duplication in the CMT1A patients.  Skin fibroblasts were 
also obtained from two unrelated healthy controls for hiPSC generation, and hESC 
line H9 was used as an additional control (Table 1).  CMT1A and control fibroblasts 
were reprogrammed into hiPSCs using non-integrating Sendai virus delivery of the 
four Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC).  The resulting hiPSC 
colonies are positive for several classical pluripotency markers, including NANOG, 
TRA1-60, TRA1-81, SSEA3, and SSEA4 (Fig. 3-2).  Because the epigenetic 
reprogramming process can introduce chromosomal rearrangements and the cell 
culture process can select for genomic rearrangements conferring a growth 
advantage, it is also important to verify that all the hiPSC lines have normal 
karyotypes96 (Fig. 3-3A).  In addition, because of the use of Sendai virus to deliver 
the four reprogramming transcription factors, it is important to make sure that the 
Sendai virus is no longer present in the hiPSC culture after several passages; long-
term presence of Sendai virus would likely alter the differentiation propensity of the 




there is no residual Sendai virus contaminating our hiPSC cultures (Fig. 3-3B).  
From three starting fibroblasts, a total of 18 hiPSC clones were ultimately created.  
It is well established that different hiPSC clones have varying propensity to 
differentiate towards different lineages94, and that expression of certain RNAs and 
microRNAs can predict whether an hiPSC clone will differentiate more readily 
towards neuronal lineages97,98 (as opposed to remaining undifferentiated or tending 
towards mesodermal and endodermal lineages).  We screened our 18 clones for 
expression of the genes HHLA1 and LincROR, which were shown by Shinya 
Yamanaka’s group to predict clones would be differentiation-defective versus 
differentiation competent98.  In addition, we also screened all our clones for 
microRNA 371 cluster expression, which was shown by Kim, et al to predict 
differentiation towards neuronal lineages99.  Based on the results of our screens 
(data not shown), five CMT1A hiPSC clones representing three patients were chosen 
for Schwann cell differentiation.   
CMT1A and control hiPSCs can generate Schwann cells with comparable yield and 
Schwann cell marker gene expression levels  
 These CMT1A hiPSCs (and control hiPSCs) were then differentiated into 
Schwann cells using the LSB2i protocol developed in chapter 2 of this dissertation 
After following the LSB2i differentiation scheme for 21-23 days, the Schwann cells 
were FACS purified using an antibody against Schwann cell alpha4 integrin, CD49d.  
Over the course of dozens of control (n=28) and CMT1A (n=95) hiPSC 
differentiation batches, it was found that both populations give rise to similar 




PCR to examine the enrichment of Schwann cell genes cadherin 19 (CDH19) and 
myelin protein zero (MPZ) between the CD49d+ Schwann cell fraction and the 
CD49d- non-Schwann cell fraction, providing a quality control metric for FACS 
purification efficacy.  In both the control and CMT1A Schwann cell purifications, no 
significant differences were found between CDH19 and MPZ enrichment in control 
hiPSC-derived Schwann cells and CMT1A hiPSC-derived Schwann cells (Fig.3-4B).  
These experiments demonstrate that the CMT1A and control hiPSC lines all yield 
similar percentages of Schwann cells with similar Schwann cell lineage gene 
enrichment levels, making them a fair platform for further molecular studies. 
CMT1A hiPSC-derived Schwann cells upregulate PMP22 gene expression relative to 
controls  
 Next we looked at the PMP22 gene expression levels of the CMT1A Schwann 
cells versus controls (Fig. 3-4C).  We found that while PMP22 expression had quite 
a broad range in both CMT1A- and control hiPSC-derived Schwann cells, overall, the 
CMT1A Schwann cells did indeed express more PMP22 (p = 0.0039).  Because 
CMT1A patients have a total of three copies of PMP22 and healthy controls have 
two copies of PMP22, 1.5x more PMP22 expression in the CMT1A hiPSC-derived 
samples might theoretically be expected.  Yet, the variability in PMP22 gene 






Microarray profiling of CMT1A hiPSC-derived Schwann cells and controls reveals 
upregulation of a non-PMP22 CMT1A duplicated region gene, as well as upregulation 
of inflammatory signaling pathways  
 To find global gene expression differences between CMT1A hiPSC-Schwann 
cells and controls, four independently differentiated samples from CMT1A hiPSCs 
(three samples from one clone from patient 5148, one sample from one hiPSC clone 
from unrelated patient 5165) and controls (two samples from one clone from 
control patient 2623, two samples from hESC line H9) were submitted for 
microarray analysis.  Samples were collected immediately after FACS purification, 
and were selected for a minimum of 1.5-fold PMP22 upregulation by qRTPCR.  The 
Affymetrix Human Primeview array was chosen as it profiles expression of 49,000 
probes for well characterized genes.  In Fig.3-5, a volcano plot of microarray 
results can be viewed, with Log2(fold change in gene expression) on the x-axis, and 
the significance of that fold change, -Log(p-value), on the y-axis.  Overall, it is 
apparent that several genes are upregulated in the CMT1A hiPSC-Schwann cells 
relative to controls.  Notably, PMP22 is 1.74-3.14 fold upregulated in the profiled 
CMT1A samples, and HS3ST3B1, another gene from the CMT1A duplicated region, 
is upregulated 3.07-5.35 fold.  The upregulation of HS3ST3B1 is very interesting as 
it is located in the CMT1A duplicated region, but previously has not been studied in 
CMT1A pathogenesis (Fig. 3-1B).  The Primeview array also contains probes for a 
handful of other genes from the CMT1A duplicated region, and while none of those 
appear to be differentially expressed (Fig. 3-8), it is indeed possible that other 




may be found to be differentially expressed by RNA-sequencing analysis in a future 
study.   
 To better understand the broader patterns characterizing the differentially 
expressed genes, all the genes that were differentially expressed at least 3 
standard deviations from the mean (corresponding to a fold change of 2.9x higher 
expression in CMT1A samples) were analyzed with Ingenuity Pathway Analysis 
(IPA; Canonical Pathways function) and DAVID (Biological Process, Cellular 
Components, and Biocarta functions).  One clear theme was that several 
inflammatory pathways appeared to be implicated in several types of gene ontology 
analysis: the complement cascade, humoral immunity, granulocytes and 
agranulocytes, chemotaxis and cytokine response pathways all received statistically 
significant scores (Fig. 3-6).  To validate these results, several genes of interest 
were selected based on the IPA and DAVID results (Fig. 3-5, marked genes) and 
evaluated with qRTPCR on biologically independent samples from additional CMT1A 
hiPSC clones and genotypes (Fig. 3-7A).  hiPSC-Schwann cells from five hiPSC 
clones representing three CMT1A patients were represented.  Although it is 
apparent that there is quite a bit of variability in expression levels of these genes, 
there appears to be a pattern of increased inflammatory gene expression 
(specifically, TGFBi, p<0.0001; CXCL14, p<0.001; CXCL12, p<0.01; IL1R1, 
p<0.01, IL8, p<0.05) in CMT1A hiPSC-Schwann cells relative to controls.   





This implores the question of whether the upregulated inflammatory gene 
expression translates into increased inflammatory protein expression.  To 
investigate inflammatory protein expression, commercially available cytokine array 
panels were purchased from R&D systems.  These panels consist of a membrane 
spotted with antibodies to 36 different cytokines, chemokines, complements, and 
acute phase proteins, and using method similar to a sandwich ELISA, inflammatory 
proteins secreted by Schwann cells into their tissue culture media can be assessed.  
The results of our study (Fig. 3-7b) demonstrate statistically significant 
upregulation of 14 of the 36 proinflammatory proteins profiled, including CXCL1100–
104 (p<0.05), IL-6105–108 (p<0.01), IL-8109,110 (p<0.01), MCP-1110–115 (p<0.01), and 
sTREM-1 (p<0.001)116.  Most pro-inflammatory cytokines have multiple functions in 
different contexts, but two common themes among all these particular proteins are 
that they can either recruit monocytes/macrophages or neutrophils to areas of 
tissue damage.  These observations indicate that CMT1A hiPSC-Schwann cells 
secrete increased levels of monocyte and neutrophil chemotactic agents, which in 
turn suggests that endogenous Schwann cells of CMT1A patients may also secrete 














Figure 3-1.  A. Schematic of the reprogramming methods used to 
generate CMT1A patient hiPSC derived Schwann cells from CMT1A 
patient fibroblasts.  B. The 1.4MB CMT1A duplicated region on 
chromosome 17 present in CMT1A patients, with the region 




Table 3-1: Control and CMT1A lines included in this study 
Type Age (years) Sex # clones 
CMT1A (5148) 17 M 3 
CMT1A (5165) 51 M 7 
CMT1A (5167) 28 F 8 
Healthy control 
(2623) 
61 F 4 
Healthy control 
(01582) 
11 F 8 
Embryonic stem 
cell (H9) 






Figure 3-2: CMT1A patient-derived hiPSCs exhibit clonal morphology and 








Figure 3-2.  CMT1A and control hiPSCs acquire clonal morphology 
and express human stem cell pluripotency markers.  Representative 















Figure 3-3.  A. CMT1A hiPSC lines from three different patients exhibit 
normal karyotypes, as demonstrated by representative images from 
cytogenetic analysis.  B. PCR for Sendai virus transgenes 
demonstrate that CMT1A hiPSCs and control lines do not express 















Figure 3-4.  A. FACS purification of LSB2i treated CMT1A and control 
hiPSCs reveals similar yields of CD49d+ Schwann cells. Control n=36, 
CMT1A n=99, p-value=ns, unpaired t test. Data expressed as mean +/- 
SD. B. Post-FACS evaluation of Schwann cell gene enrichment in 
CD49d+ Schwann cells versus matched CD49d- non-Schwann cells, by 
real time PCR. Control n=11 for CDH19, n =15 for MPZ. CMT1A n=28 for 
CDH19 and n = 37 for MPZ. p =ns by unpaired t test. C. Real time PCR for 
PMP22 in CMT1A and control CD49d+ Schwann cells. Data expressed as 












 Figure 3-5.  Volcano plot representation of microarray array expression 
profiling of four biologically independent CMT1A hiPSC-Schwann cells 
samples and four biologically independent control hPSC-Schwann cell 
samples with PMP22 fold change greater than 1.5. Select genes of 




Figure 3-6: Gene ontology and pathway analysis of CMT1A hiPSC-Schwann 






 Figure 3-6.  Results from DAVID gene ontology and Ingenuity Pathway 













Figure 3-7.  A. Real time PCR validation of microarray results in 
biologically independent samples from 5 hiPSC clones representing 3 
CMT1A patients. Data expressed as fold change versus gene expression 
in control hiPSC-derived Schwann cells. * p<0.05, ** p<0.01, ***, p<0.001, 
**** p<0.0001, ratio paired t test.  B. Cytokine array profiling of cell 
conditioned medium from Day 10 post-FACS CD49d+ Schwann cells. 
Data expressed as fold change in protein expression between CMT1A 
Schwann cells versus matched control. Data from independent 
differentiations are displayed as different colors. * p<0.05, ** p<0.01, ***, 



































Figure 3-8.  Volcano plot visualization of CMT1A duplicated region 
probes included on the Affymetrix human primeview array.  X-axis 
displays the log2(fold change) in expression of a given gene in CMT1A 





CMT1A is not clinically thought of as inflammatory disorder, although there is 
increasing laboratory evidence to support this idea23,117–119.  Our study found 
statistically significant upregulation of several cytokines, and of those cytokines, 
CXCL1, IL-6, IL-8, MCP-1, and STREM-1 have particularly large magnitudes of 
upregulation.   
MCP-1, which has the most dramatic magnitude of upregulation, is known to 
be expressed by Schwann cells in other pathological contexts, such as Wallerian 
degeneration120–122.  It is a potent monocyte/macrophage chemoattractant114,115, 
and has been implicated in CNS neurodegenerative diseases as well120.  CXCL1, in 
contrast, appears largely to mediate neutrophil recruitment100–103, with only one 
report of its role in monocyte recruitment104.  IL-6 has previously been reported as 
being produced by injured Schwann cells50, and is involved in both neutrophil108 and 
monocyte105,106,121 chemotaxis.  One study even suggests that it acts as a switch 
between neutrophil and monocyte recruitment107.  Similarly, IL-8 also seems to 
mediate both neutrophil and monocyte chemotaxis109,110.  STREM-1, is the soluble 
form of TREM-1, which is an Ig superfamily receptor whose binding induces 
secretion of IL-8, MCP-1, and other cytokines as well as the activation of 
neutrophils and monocytes during acute inflammation116. 
As these cytokines largely function as either neutrophil or monocyte 
chemoattractants, it implies that those cell types might be pathologically recruited 
to CMT1A patient myelin and contribute to nerve damage.  This idea is corroborated 




found that two different CMT1A mouse models overexpressing PMP22 (the C22 and 
C61 models) and one model with a PMP22 point mutation (the Trembler-J model) 
all exhibit increased macrophage infiltration in their nerves23,118,119.  Furthermore, 
the Martini group found that they found that macrophage infiltration in the C22 
mouse is largely mediated by increased MCP-122, one of the very proteins 
upregulated in our cytokine array panel.  The Martini group’s results largely 
corroborate our own, demonstrating that our hiPSC-based studies can indeed yield 
relevant and reproducible findings.   
Our study may also help illuminate two questions that currently remain 
unaddressed by in vivo rodent or clinical studies.  One such question regards the 
role of the leukocytes recruited to CMT1A nerve lesions.  Are these leukocytes a 
secondary source of pathology, responding to phagocytose myelin debris from 
chronic myelin damage?  Or are they a source of primary pathology, being recruited 
to undamaged nerves and actively mediating their destruction.  Our data, taken 
from Schwann cell precursors that have been differentiated for only 31-33 days 
(21-23 days pre-FACS, 10 days post-FACS), suggests that the latter is the case.  
Schwann cell precursors, the earliest member of the Schwann cell lineage, likely 
best mimic the status of human fetal Schwann cells.  If a patient’s endogenous 
Schwann cells precursors are secreting such high levels of pro-inflammatory 
cytokines, it implies that leukocytes might be recruited early to the patient’s nerves 
and actively contribute to pathology even before symptoms become clinically 
apparent.  Alternatively, it is also quite likely that these cytokines are not acting as 
leukocyte chemoattractants in the context of CMT1A, but rather as more general 




Another question raised by rodent models of CMT1A is what cell type is 
responsible for the observed increase in macrophage recruitment to CMT1A rodent 
nerve lesions?   This question is technically difficult to address through rodent and 
clinical studies, as it would be challenging to determine which cell type within a 
nerve biopsy—a mixture of neurons, Schwann cells, fibroblasts, and others—is 
actually secreting the chemokines.  Our study though, through its use of a FACS-
purified population of Schwann cells, is well positioned to address this question, and 
our findings imply that the Schwann cells are specifically responsible for the 
secretion of the pro-inflammatory cytokines.   
Aside from the inflammatory phenotype, our CMT1A hiPSC-Schwann cells 
exhibit another novel genetic phenotype.  They overexpress the gene Heparan 
sulfate glucosamine 3-O-sulfotransferase 3B1 (HS3ST3B1 or 3-OST-3b), one of the 
genes from the CMT1A duplicated region that has not previously been reported as 
upregulated in CMT1A Schwann cells.  Heparan sulfates are linear disaccharide 
glycosaminoglycans that are found tethered to a protein core to form 
proteoglycans.  These proteoglycans are ubiquitously found as cell surface integral 
membrane proteins and also in the extracellular matrix, where they play a myriad 
of roles regulating cell-cell interactions, cell signaling, migration, adhesion, growth, 
differentiation, and more123,124.  Heparan sulfates can also bind antithrombin, 
fibroblast growth factors, vascular endothelial growth factor, interleukin-3, 
interferon-gamma, granolucyte macrophage colony stimulating factor, and many 
additional growth factors, thereby regulating coagulation, angiogenesis, and many 




their affinity for a given ligand, and these fine structures are created through the 
action of sulfotransferases (ie 3-O-sulfotransferase1, 3-O-sulfotransferase 2, etc). 
The HS3ST3B1 gene in the CMT1A duplicated region encodes one such 
sulfotransferase, specifically a type II integral membrane protein.  HS3ST3B1 is one 
of seven isoforms belonging to the 3-0-sulfotransferase family, which catalyzes the 
addition of sulfate groups to the 3-0H position of glucosamine in heparan sulfate126.  
Sulfation at the C3-OH moiety of heparan sulfate is one of the rarest heparan 
sulfate modifications, occurs late in heparan sulfate biosynthesis, and can be 
regulated in a tissue specific manner (due to the availability of a multitude of 
isoforms), making 3-O-sulfonation a rate limiting step that is likely an important 
regulator of numerous biological processes127,128.   
The HS3ST3B1 enzyme is expressed in a broad range of tissues and is 
particularly enriched in liver and placenta129.  Whereas two other isoforms (HS3ST2 
and HS3ST4) appear to be the predominant isoforms expressed in the nervous 
system, one study found low, yet certainly detectable, HS3ST3B1 expression in the 
trigeminal ganglia128.  Interestingly, that study did not detect any HS3ST3B1 gene 
expression in axonal/Schwann cell biopsies, yet our study does find it expressed in 
Schwann cells.   
Various functions have already been ascribed to HS3ST3B1 in pathological 
contexts.  It can mediate viral entry of Herpes Simplex Virus-1 (HSV-1) into cells, 
as its overexpression has been found to convert HSV-1 resistant cells to HSV-1 
susceptible cells124,130.  HS3ST3B1 can also induce the epithelial mesenchymal 




line131.  Linkage analysis of a family with autosomal dominant idiopathic sclerosis 
mapped the likely genetic cause to either HS3STB1 or the nearby HS3STA1, 
suggesting the gene may play a role in musculoskeletal development132, though it 
should be noted that no specific mutations in HS3STB1 could actually be identified 
in that study.  More generally, the broader family of 3-O-sulfotransferases (which 
includes HS3ST1, HS3ST2, HS3ST3, etc) has been found to be a key regulator 
between production of an anticoagulant form of heparan sulfate, versus a non-
anticoagulant form of heparan sulfate, though HS3ST1 appears to be the major 
isoform mediating this role127.   
As to the specific function of HS3ST3B1 in Schwann cells, further 
investigation is warranted.  A literature search didn’t produce any previous 
publications on HS3ST3B1 action in Schwann cells or myelin.  A search on HS3STB1 
roles in the central nervous system produced one marginally relevant paper on HIV 
neuroimmunology133.  A group cloned the Tat gene from patients with HIV and HIV-
dementia and overexpressed it in monocytoid lines; they found a specific induction 
of the HS3ST3B1 gene when using the HIV-dementia Tat clone, and an induction of 
the MCP-1 gene when overexpressing either Tat clone.  Their results have some 
commonalities with our results (CMT1A Schwann cells upregulate HS3STB1 gene 
and MCP-1 protein), but it is unclear whether any broader meaning can be 
ascertained from these parallels.  Perhaps HS3STB1 plays a role in neuroimmune 
regulation – the best way to determine its specific role in the context of our study 





In summary, in this profiling of CMT1A patient hiPSC-derived Schwann cells, 
we found upregulation of several pro-inflammatory cytokines and upregulation of 
HS3ST3B1, a gene from the CMT1A duplicated region.  As exciting as our results 
may be, there are some limitations that should be kept in mind.  First of all, 
individual hiPSC lines vary quite dramatically in their in vitro behavior, meaning 
their differentiation capacity and gene expression profiles.  For instance, it has been 
found that two different hiPSC lines derived from the same patient can vary as 
much as hiPSC lines from two different patients94.  Consequently, it is prudent to 
validate all hiPSC results using a second method.  In the stem cell field, most hiPSC 
studies are validated through use of genetically manipulated congenic lines.  That 
is, genome editing is used to either correct a genetic mutation in a disease hiPSC 
line or introduce a genetic mutation to a control hiPSC line.  By maintaining a 
constant genomic background, such studies can control for the variable 
“personalities” of hiPSC lines and demonstrate that a given phenotype is specific to 
the mutation of interest.  The large 1.4MB size of the CMT1A duplicated region 
makes genetic correction challenging, so our validation studies will be performed 
using an alternative method in Chapter 4. 
Another caveat of our results is that these studies were performed under in 
vitro settings, using serum containing tissue culture media to presumably induce 
cytokine release.  In an in vivo setting, under different environmental conditions, 
the same combination of cytokines may not be released from the Schwann cells, 
though the Martini group’s in vivo corroboration of our in vitro MCP-1 upregulation 





 CMT1A patient hiPSC-derived Schwann cells express higher levels of PMP22 
and heparan sulfate sulfotransferase HS3ST3B1 transcripts, as well as higher levels 
of several inflammatory gene transcripts and proteins.  It implies that immune 
signaling dysregulation may be a pathologic feature of CMT1A, that this 
dysregulation is a Schwann cell intrinsic phenomenon, and suggests that leukocyte 
recruitment to early nerves may be a primary contributor to CMT1A pathogenesis, 
rather than a late reaction to myelin damage.  If these results can be validated by a 
second model, it may compel us to reexamine our current understanding of CMT1A 








CHAPTER 4: VALIDATION OF THE CMT1A HIPSC PHENOTYPE WITH TWO 





Most disease modeling studies in the stem cell field are currently performed 
using human induced pluripotent stem cells (hiPSCs), yet there also exist two other 
methods for generating patient-derived cells that can be harnessed to model 
disease.  One such method is direct lineage reprogramming, also known as 
transdifferentiation, in which one somatic cell type, typically a fibroblast, is 
epigenetically reprogrammed into a another somatic cell type.  The resulting cell is 
generally referred to as a “directly converted” or “induced” cell.  Methods have 
already been generated for direct lineage reprogramming into myoblasts134, 
pancreatic B-islet cells135, neurons136, neural progenitors137, motor neurons138, 
oligodendrocytes139,140, neural crest141, hematopoietic cells142, and many more cell 
types, and their ability to model human diseases in vitro has been established as 
well141,143,144.   
Another source of patient-derived cells for disease modeling are embryonic 
stem cell lines from blastocysts with a preimplantation genetic diagnosis (PGD) of a 
disease of interest.  PGD is a technique that allows for genotyping of IVF-generated 
embryos in couples carrying145 a serious genetic defect.  A representative cell is 
biopsied three to four days post-fertilization and tested for the genetic defect, and 
unaffected embryos can be transplanted into the carrier.  The inner cell mass of 
affected embryos may be cultured to establish an embryonic stem cell line (PGD-
hESC) that can be used to further study the disorder caused by the genetic variant.  
The NIH Stem Cell Repository has a limited yet growing collection of PGD-hESC 




mutations causing Duchenne muscular dystrophy, spinal muscular atrophy, 
Huntington’s disease, hemophilia B, hypertrophic cardiomyopathy, hydroxysteroid 
dehydrogenase deficiency, cystic fibrosis, fascioscapulohumoral muscular 
dystrophy, multiple endocrine neoplasia 2A, and many more.  It may be argued 
that using a PGD-hESC line is preferable to using a control hESC line with an 
engineered mutation, as it eliminates possibility of off-target effects also allows for 
expression of the genetic variant with the most physiologically relevant timeline and 
tissue expression pattern.  If CMT1A were modeled through genetic manipulation of 
control hESC lines, a priori assumptions would also need to be made about which 
genes from the 1.4 MB CMT1A duplicated region should be overexpressed, what 
dosage of overexpression should be used, where those genes should be inserted in 
the genome, and under which promoter, and use of PGD-hESC lines the need to 
make such assumptions.  Thus far, Huntington’s disease146 and Fragile X-
Syndrome147 have been successfully modeled using PGD-hESC lines, though hiPSC-
based disease modeling has largely overshadowed use of PGD-hESC lines.  
Presumably, as additional PGD-hESC lines are deposited into the NIH repository this 
disparity may narrow.   
In chapter 3, we modeled the CMT1A using patient-hiPSC derived Schwann 
cells.  However, as previously discussed, hiPSC based data can be quite variable 
and should ideally be validated using alternative methods.  Generally, genome 
editing is used to introduce a mutation into control hiPSCs or to correct a mutation 
in disease hiPSCs, to control for genomic background and demonstrate that an 




In contrast, here we propose to validate our CMT1A hiPSC data using two 
other sources of reprogrammed CMT1A Schwann cells.  We have obtained two 
embryonic stem cell lines derived from blastocytes that have a pre-implantation 
genetic diagnosis of CMT1A (referred to as CMT1A PGD-hESC lines).  Schwann cells 
can be obtained from these CMT1A PGD-hESC lines through the same LSB2i 
protocol developed in Chapter 2 and used for CMT1A hiPSC disease modeling in 
Chapter 3.  In addition, our lab has recently published a method for the direct 
conversion of fibroblasts into neural crest (termed iNC, or induced neural crest)141, 
which can be further differentiated into Schwann cells (termed iNC-SC).  The same 
CMT1A patient fibroblasts that were used to generate CMT1A hiPSCs can also be 
directly converted into CMT1A iNC-SC, therefore controlling for genotypic 
differences between the cell lines.   
 In Figure 4-1 we can see a diagram of Waddington’s epigenetic landscape 
and how hiPSC-Schwann cells, PGD-hESC-Schwann cells, and iNC-Schwann cells all 
fit within that paradigm.  Use of all three methods of generating patient-derived 
reprogrammed cells has never been previously implemented, and utilizing three 
congruent models (Figure 4-2) to find a converged phenotype offers a novel 






CMT1a Preimplantation Genetic Diagnosis embryonic stem (PGD-hESC) cell line 
generation 
Two embryonic stem cell lines with a preimplantation genetic diagnosis of CMT1A 
were obtained from the NIH Human Embryonic Stem Cell Repository (HUES PGD11 
and 12; NIH registration numbers 94 and 95; NIH approval numbers NIHhESC-11-
0094 and NIHhESC-11-0095).  Embryonic stem cell lines were generated from 
blastocysts that were determined to have the CMT1A duplication through pre-
implantation genetic diagnosis, and genomic DNA real time PCR was used to verify 
the presence of the PMP22 duplication in the resulting hESC lines.  A Materials 
Transfer Agreement was performed with Harvard University, and all work 
performed at Johns Hopkins University was under guidance of the JHU Institutional 
Stem Cell Research Oversight Committee (ISCRO). 
CMT1A PGD-hESC line generation was perfomed by Benjamin Lannon, a clinical 
fellow in the laboratory of Kevin Eggan, Harvard Stem Cell Institute. 
Schwann cell differentiation from CMT1A PGD-hESC cells 
CMT1A and control hiPSCs were plated and differentiated into putative Schwann 
cells, as described extensively in Appendix 1.  Briefly, colonies of pluripotent cells 
were rendered into single cells and plated on Geltrex, an artificial basement 
membrane-like matrix.  They were then treated with a combination of small 
molecules to induce neuronal and Schwann cell differentiation: 




containing 10 µM SB-431542 and 500 nM LDN-193189 (day 0).   
2. On day 2 of differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542, 500 nM LDN-193189, 3 µM CHIR 99021, 10 
µM DAPT.  (activates WNT while blocking gamma secretase/Notch) 
3. On day 4 of differentiation, aspirate the medium and add KSR/NB (3:1) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT (final 
concentrations are for the combined KSR/NB mixture). 
4. On day 6 of differentiation, aspirate the medium and add KSR/NB (1:1) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT. 
5. On day 8 of differentiation, aspirate the medium and add KSR/NB (1:3) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT. Some toxicity may 
be observed that is inversely correlated with efficiency of SOX10 induction. 
6. On day 10 of differentiation, aspirate the KSR/NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
7. On day 14 of differentiation, aspirate the NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
8. On day 18 of differentiation, aspirate the NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
9. Maintain in this manner until day 21-23 of differentiation, when the cells 
are ready for purification. 
 




The FACS protocol is described extensively in Appendix 1.  Briefly, Schwann cells 
were purified with Fluorescence Activated Cell Sorting (FACS) after 21-23 days of 
differentiation using a PE-conjugated antibody to the alpha4 integrin, CD49d (R&D 
Systems, FAB1354P).  After FACS, Schwann cells were replated onto tissue culture 
plates treated with fibronectin (R&D Systems, 1918-FN-02M) and laminin (Cultrex, 
R&D Systems, 3400-010-1) coated plates.  (Plates were coated with 1ug/mL 
laminin and 2ug/mL fibronectin in PBS for 24 hours).  Cells were maintained in 
culture for up to 80 days post-FACS using Neurobasal medium (Life Technologies, 
21103-049) supplemented with L-glutamine (Life Technologies, 25030-081), B-27 
supplement (Life Technologies, 12587-070), N2 supplement (Life Technologies, cat. 
no. 17502-048), and 1% fetal bovine serium (Hyclone, cat. no. SH30070.03). 
CMT1a Induced Neural Crest-derived Schwann cell generation 
Three CMT1A patient fibroblasts and two matching controls were reprogrammed 
into induced neural crest (iNC) and FACS purified using methods previously 
published by the Lee Lab141.  FACS purified iNC were maintained in Neurobasal 
medium containing 1 ug/ml of doxycycline for 3 days, followed by one more week 
of incubation with hESC-derived Schwann cell conditioned medium supplemented 
with CNTF (10 ng/ml) and NRG1 (20 ng/ml), without doxycycline. To stimulate 
cytokine release, medium was changed to Neurobasal + 1% fetal bovine serum for 
the last 3 days.  Cells were maintained in culture for 2-5 weeks post-FACS. 
This work was performed in collaboration with Yong Jun Kim, a postdoctoral fellow 





Cells were fixed in 4% Paraformaldehyde for 20 minutes, then blocked and 
permeablized in 0.5%BSA and 0.1% Triton X-100 in PBS for 30 minutes.   Primary 
antibodies were diluted 1:100 to 1:500 in 0.5%BSA and 0.1% Triton X-100 in PBS 
and samples were incubated overnight at 4 degrees.  Secondary antibodies were 
diluted 1:1000 in 0.5%BSA and 0.1% Triton X-100 in PBS, and incubated 2 hours 
at room temperature.  Primary antibodies can be found in Appendix 2.  Appropriate 
488, 568, and 647-conjugated Alexa fluor secondary antibodies were utilized.  
RNA extraction and real time PCR 
Cells were homogenized in Trizol Reagent (Life Technologies, 15596-026) and 
manufacturer’s protocols were followed to extract total RNA.  0.5 ug total RNA was 
reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, 4387406).  Real time PCR was performed on an Eppendorf 
Realplex Mastercycler Ep gradient S.  Cycling conditions are as follows: 95 degrees 
2 min, 40 cycles (95 degrees 3 seconds, 60 degrees 30 seconds).  Primer probes 
can be found in Appendix 2.  Data from real time PCR for microarray validation 
probes in were displayed as fold change in CMT1A sample expression versus 
median gene expression in controls, and analyzed with the ratio paired t-test.   
Cytokine expression profiling of CMT1A PGD-hESC- and iNC-Schwann cells  
For secreted protein profiling in PGD-hESC-Schwann cells, upon FACS purification, 
matched pairs of CMT1A and control PGD-hESC-Schwann cells with at least 1.5-fold 
upregulation of PMP22 were identified.  FACS purified CD49d+ Schwann cells were 
maintained in culture for 10 days post-FACS.  For secreted protein profiling in iNC-




Schwann cells with at least 1.5-fold upregulation of PMP22 were identified.  Cells 
were maintained in culture for 2-5 weeks, and to stimulate cytokine release 
medium was changed to Neurobasal + 1% fetal bovine serum for the last 3 days.  
Cell conditioned medium was profiled with the Human Cytokine Array Kit (R&D 
Systems, ARY005) according to manufacturer’s instructions, and fold change in 
expression of a given protein in CMT1A Schwann cells versus control Schwann cells 
were reported. 
Cytokine expression profiling of CMT1A and control patient samples 
De-identified sural nerve biopsies from two patients with genetically proven CMT1A 
and two histologically normal samples from non-CMT1A patients were obtained 
from the Johns Hopkins Neuromuscular Histopathology Laboratory under an 
appropriate Institutional Review Board protocol.  Lysates were obtained by 
sonicating nerve biopsies in RIPA buffer, and equal amounts of protein were then 
used for secreted protein expression profiling. 
Transwell migration assay 
THP-1 human monocyte chemotaxis assays were performed by using the HTS 
transwell plate system (5μm pore size, Corning). Schwann cell conditioned medium 
was collected from Day 10 post-FACS hiPSC- and PGD-hESC-Schwann cells, and 2-
5 week post FACS iNC-Schwann cells. 100uL of Schwann cell conditioned medium 
was placed in bottom well with or without anti-MCP1 (R&D). THP-1 monocytes were 
resuspended in Neurobasal medium (Gibco) + 1% FBS to a concentration of 2.5 
million cells/mL, and 100ul was placed in upper wells. After 3 hrs incubation in 37 





CMT1A hiPSC-Schwann cells were incubated with 10 uM each of bortezomib, 
fenretinide, and olvanil for 24 hours. Total RNA was utilized for PMP22 real time 
PCR, and cell conditioned medium was used for secreted protein expression 
profiling. 
Statistical analyses 
Data was analyzed using Graphpad Prism 6.  Means +/- standard deviation are 
plotted, and p-values were calculated using the unpaired t test, ratio paired t test, 






CMT1A PGD-hESCs exhibit colony morphology, express classical pluripotency 
markers, are karyotypically normal, and harbor the CMT1A duplication 
 Two independent embryonic stem cell lines with a preimplantation genetic 
diagnosis (PGD-hESC) of CMT1A were obtained, and we verified their pluripotency 
marker expression by immunofluorescence, normal chromosomal architecture by 
karyotype analysis, and presence of the CMT1A duplication by fluorescence in situ 
hybridization (FISH) (Fig. 4-3B-D).   
CMT1A PGD-hESC-derived Schwann cells exhibit comparable Schwann cell yields, 
Schwann cell gene enrichment levels, and increased PMP22 gene expression 
relative to controls 
These CMT1A PGD-hESC lines were then differentiated into Schwann cells using the 
LSB2i protocol developed in Chapter 2 (Fig. 4-3A), and the human embryonic stem 
cell line H9 was used as a control.  After 21-23 days of differentiation, the Schwann 
cell populations were FACS-purified by staining for CD49d, an antibody we 
identified in Chapter 2 as being selective for the Schwann cell population.  From 
Fig. 4-4A it can be seen that both the control and CMT1A PGD-hESC lines yield 
similar percentages of CD49d+ Schwann cells. As a quality control measure, with 
each differentiation and FACS purification, we harvested both the CD49d+ 
(Schwann cell) fraction and the CD49d- (non-Schwann cell) fraction, and used real 
time PCR to validate that Schwann cell marker genes are indeed enriched in the 
CD49d+ (Schwann cell) population relative to the CD49d- (non-Schwann cell) 




enriched for the Schwann cell lineage markers Cadherin 19 and Myelin Protein Zero, 
verifying that our FACS purification system is indeed selecting for Schwann cells.  
We also found no significant differences between Schwann cell marker enrichment 
in control and CMT1A PGD-hESC-derived Schwann cells (Fig. 4-4B).  Next, we 
assessed their PMP22 expression levels (Fig. 4-4C), and found that while the 
PMP22 expression levels are quite variable, on average the CMT1A PGD-hESC 
Schwann cells express more PMP22 than the controls, reflecting the PMP22 
enrichment seen in the CMT1A patient biopsies15 and our CMT1A hiPSC-derived 
Schwann cells of chapter 3.   
CMT1A PGD-hESC-derived Schwann cells upregulate gene and protein expression of 
multiple pro-inflammatory cytokines 
The real time PCR probes used to validate the CMT1A microarray data from Chapter 
3 (Fig. 3-7A) were also evaluated in CMT1A PGD-hESC Schwann cells (Fig. 4-5A).  
The rationale was to determine whether these particular inflammatory genes 
overexpressed in CMT1 hiPSC-Schwann cells were also overexpressed in the CMT1A 
PGD-hESC-Schwann cells.  Upregulation of these genes in the CMT1A PGD-hESC 
lines is more modest than their upregulation in CMT1A hiPSC lines (with MCP1, 
CXCL14, IL1R1, and TGFB1 upregulation reaching statistical significance), which is 
not necessarily surprising given that these lines were never included in the initial 
microarray experiment used to select the real time PCR probes (Fig. 3-5).  
Subsequent to looking at expression levels of inflammatory genes, we also 
examined inflammatory protein expression levels through the same cytokine array 




of several proteins (CXCL1, sICAM-1, IFN-γ, MCP-1, MIF, TNF-α, and STREM-1), 
mirroring the results seen in CMT1A hiPSC-Schwann cells in Chapter 3.  In 
particular, of the 36 cytokines profiled, MCP-1, CXCL1, and sTREM-1 are commonly 
upregulated in both CMT1A hiPSC-Schwann cells and PGD-hESC-Schwann cells, 
strengthening the idea that they may play a role in CMT1A pathogenesis.  The fact 
that multiple inflammatory proteins were commonly upregulated in both the CMT1A 
hiPSC-Schwann cells and PGD-hESC-Schwann cells increases confidence in our 
hypothesis that pro-inflammatory cytokine release may be an early pathological 
feature of CMT1A and an intrinsic property of human CMT1A Schwann cells. 
CMT1A iNC-Schwann cells and controls exhibit classical Schwann cell bipolar 
morphology, are immunoreactive for Schwann cell markers, and upregulate PMP22 
gene expression 
 To further validate this result, we also utilized a third CMT1A model available 
to our lab, fibroblasts that have been directly converted into Schawnn cells (termed 
induced neural crest-derived Schwann cells or iNC-Schwann cells).  Whereas hiPSC-
derived Schwann cells are made by de-differentiating fibroblasts into induced 
pluripotent stem cells and subsequently re-differentiating them into Schwann cells, 
in this experiment we directly convert fibroblasts into multipotent neural crest and 
subsequently differentiate them into Schwann cells (Fig. 4-6A).  This technique 
bypasses the pluripotent stem cell stage, and may yield a Schwann cell population 
with a different epigenetic footprint than the hiPSC- and PGD-hESC-derived 
Schwann cells.  Interestingly, because reprogrammed cells often retain some 




stage, it is possible that the iNC-Schwann cells maintain a more mature epigenetic 
footprint than the other two Schwann cell models utilized, though this needs to be 
further investigated in future experiments.   
 CMT1A iNC-Schwann cells were generated using fibroblasts from three 
CMT1A patients, two of which were included in our earlier hiPSC study in Chapter 3 
(Table 4-1).  These fibroblasts were directly converted into induced neural crest 
(iNC) using Sox10 overexpression and Wnt pathway activation for 14 days.  On day 
14, they were then FACS purified using an antibody to CD34, a cell surface marker 
which is specifically expressed on our induced Neural Crest.  After FACS, the 
induced neural crest were replated in Schwann cell differentiation media for 2-5 
weeks.  The result is a pure Schwann cell population, as evidenced by all of the 
DAPI-positive nuclei also staining robustly for Schwann cell markers S100b and 
GFAP and exhibiting an elongated morphology stereotypical of Schwann cells (Fig. 
4-6B).  Real time PCR was used to evaluate PMP22 expression levels in both 
CMT1A and control iNC-Schwann cells, and again expression levels were variable 
with generally higher PMP22 expression in CMT1A iNC-Schwann cells versus 
controls (Fig. 4-6C, p=0.0025), mirroring what was found in our CMT1A hiPSC-
Schwann cells, CMT1A PGD-hESC-Schwann cells, and patient biopsies15.   
CMT1A iNC-Schwann cells upregulate gene and protein expression of multiple pro-
inflammatory cytokines 
Again, expression of a panel of inflammatory genes was evaluated, and those genes 
were chosen based on microarray profiling of CMT1A hiPSC-Schwann cells in 




were quite variable, yet many do appear to be upregulated, including MCP-1 
(p<0.001), CXCL1 (p<0.01), CXCL14, (p<0.01), and IL1R1 (p<0.01) (Fig.4-7A).  
In parallel, cell conditioned medium from CMT1A iNC-Schwann cells were profiled 
using an inflammatory protein panel, and it was found that several immune 
mediators are upregulated in the CMT1A iNC-Schwann cells relative to controls, 
most robustly CXCL1 (p<0.0001), MCP-1 (p<0.001), and RANTES (p<0.01) (Fig. 
4-7B).    
Comparison across three congruent models yields a converged phenotype of CXCL1 
and MCP-1 protein upregulation that can be validated in CMT1A patient nerve 
biopsies 
By comparing across the hiPSC, PGD-hESC, and iNC systems, ultimately two 
proteins, CXCL1 and MCP-1, were found to be upregulated among all three 
congruent models, resulting in a converged phenotype (Fig. 4-8A). To verify the 
increased levels of CXCL1 and MCP-1 expression in CMT1A patients, sural nerve 
biopsies were obtained. As shown in Fig. 4-8B, nerve biopsies from two genetically 
diagnosed CMT1A patients show significantly enriched levels of CXCL1 and MCP-1 
proteins over control samples.  
Three congruent models of CMT1A Schwann cells induce increased monocyte 
chemotaxis, in an MCP-1 dependent manner 
Furthermore, to determine whether this increased cytokine expression is 
sufficient to induce monocyte chemoattraction, a transwell migration assay was 
used to evaluate THP-1 human monocyte migration towards CMT1A and control 




increased numbers of THP-1 monocytes migrate towards CMT1A Schwann cell 
conditioned medium than controls (p<0.05 to p<0.0001 in hiPSC-SCs (Fig. 4-9A), 
p<0.0001 in PGD-hESC SCs, p<0.0001 in iNC-SCs (Fig. 4-9B)), and inhibition of 
MCP-1 signaling through a neutralizing antibody diminishes this effect (p<0.01 in 
hiPSC-SCs, p<0.0001 in PGD-hESC-SCs, p<0.0001 in iNC-SCs). This demonstrates 
that monocytes are indeed more readily attracted to CMT1A Schwann cells in our in 
vitro model, in an MCP-1 dependent manner.  
CMT1A patient-derived Schwann cells can be used for in vitro drug testing to 
modulate PMP22 gene expression as well as CXCL1 and MCP-1 protein expression 
Another key promise of human iPSC research is the use of patient-specific 
cells in drug testing. Thus far, our data has demonstrated the feasible generation of 
disease-specific Schwann cells from multiple patient samples, and these CMT1A 
patient-derived Schwann cells display increased levels of PMP22, as well as 
upregulated protein expression of immune mediators CXCL1 and MCP-1. We next 
tested whether exposure to candidate drugs could affect any of these three 
parameters. Three candidate chemical compounds (bortezomib, fenretinide, and 
olvanil) had previously been identified through a large-scale drug screening using 
rat Schwann cell line carrying luciferase construct to monitor PMP22 expression148. 
Exposure of CMT1A hiPSC-Schwann cells to two of the three candidates drugs 
(bortezomib and olvanil) resulted in a marked reduction of the PMP22 expression,  
in only one of our CMT1A genotypes (5167 hiPSC line) (Fig. 4-10A, left, and Fig. 
4-10B). In contrast, no significant changes of PMP22 expression were observed in 




bortezomib treatment (which showed a statistically stronger effect on PMP22 
expression) on inflammatory cytokine release in the bortezomib-responsive CMT1A 
hiPSC line, and notably bortezomib treatment induced a significant decrease in the 
protein level of MCP-1, but not CXCL1 (Fig. 4-10A, right), suggesting a partial 










Figure 4-1.  A. Waddington’s epigenetic landscape and the 
relationship between three major cellular reprogramming technologies.  
B. Epigenetic relationship between hiPSC-Schwann cells, PGD-hESC-












Figure 4-2.  Experimental schematic outlining use of three congruent 











Figure 4-3  A. Overview of CMT1A PGD-hESC generation from CMT1A 
PGD blastocysts, and subsequent differentiation into Schwann cells 
precursors.  B. Pluripotent stem cell marker expression including NANOG, 
TRA-1-60, TRA-1-81, SSEA4 and SSEA4. C. Representative karyotype 
images of the PGD-hESC lines. D. Fluorescence in situ hybridization 


















Figure 4-4.  A. FACS purification of LSB2i treated CMT1A and control 
PGD-hESCs reveals similar yields of CD49d+ Schwann cells. Control 
n=27, CMT1A n=13. p=ns, unpaired t test. Data expressed as mean +/-
SD.  B. Post-FACS evaluation of Schwann cell gene enrichment in 
CD49d+ Schwann cells versus matched CD49d- non-Schwann cells, by 
real time PCR. Control n=9 for CDH19, n=9 for MPZ; CMT1A n=7 for 
CDH19, n=9 for MPZ. p=ns, unpaired t test. Data expressed as mean +/-
SD.C. Real time PCR for PMP22 in CMT1A and control CD49d+ Schwann 
cells. Control n=32, CMT1A n = 25. p<0.0001, unpaired t-test. Data 




Figure 4-5: Validation of CMT1A hiPSC-Schwann cell microarray results 









Figure 4-5.  A. Real time PCR validation of CMT1A hiPSC microarray 
results in two independent CMT1A PGD-hESC lines representing two 
different CMT1A blastocysts. Data expressed as fold change versus gene 
expression in control hESC-derived Schwann cells. * p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001, ratio paired t-test.  B. Cytokine array profiling 
of cell conditioned medium from Day 10 post-FACS CD49d+ Schwann 
cells. Data expressed as fold change in protein expression between 
CMT1A Schwann cells versus matched control. Data from independent 
differentiations are displayed as different colors. * p<0.05, ** p<0.01, *** 










Figure 4-6.  A.  Schematic of the method to directly convert CMT1A 
patient fibroblasts into CMT1A iNC-Schwann cells.  B. Representative 
immunofluorescence for GFAP and S100b in iNC-Schwann cells from two 
control fibroblasts and two CMT1A fibroblasts.  C. Real time PCR for 
PMP22 in CMT1A and control CD49d+ Schwann cells. Control n=19, 







Figure 4-7: Validation of CMT1A hiPSC-Schwann cell microarray results 











Figure 4-7.  A. Real time PCR validation of CMT1A hiPSC microarray 
results in two independent CMT1A iNC-Schwann cell lines representing 
two different CMT1A patients. Data from independent differentiations 
represented as different colors.  Data expressed as fold change versus 
gene expression in control iNC Schwann cells. * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001, ratio paired t-test.  B. Cytokine array profiling of 
cell conditioned medium from 2 weeks post-FACS iNC-Schwann cells 
derived from two different patients. Data expressed as fold change in 
protein expression between CMT1A Schwann cells versus matched 
control. Data from independent differentiations are displayed as different 




Figure 4-8: Three congruent CMT1A models reveal a converged phenotype 











Figure 4-8.  A. Venn diagram of upregulated secreted proteins in each 
model, with a converged phenotype of CXCL1 and MCP-1 upregulation. 
B. Protein expression level of CXCL1 and MCP-1 in nerve biopsies from 
two CMT1A and two control patients. Data expressed as mean +/- SD of 
cytokine dot array intensity. n=4 technical repeats per condition. * p<0.05, 




Figure 4-9: THP-1 human monocytes are more readily recruited to CMT1A 










Figure 4-9.  A. THP-1 human monocyte transwell migration assay results, 
using conditioned media of Schwann cells derived from different hiPSC 
lines. Data expressed as mean +/- SD of migrated THP-1 cells, divided by 
100. n=3 to 9 per condition. * p<0.05, ** p<0.01, **** p<0.0001, one-way 
ANOVA.  B. THP-1 human monocyte transwell migration assay results, 
using conditioned media of Schwann cells derived from different PGD-
hESC and iNC lines. Data expressed as mean +/- SD of migrated THP-1 
cells, divided by 100. n=3 to 9 per condition. * p<0.05, ** p<0.01, **** 




Figure 4-10: Pharmacological treatment can decrease MCP-1 and CXCL1 









Figure 4-10.  A. Expression level of PMP22 transcript and CXCL1 and 
MCP-1 protein from Schwann cells from a CMT1A hiPSC line (5167 #5) 
upon three compound treatment. Gene expression data displayed as 
mean +/- SD of normalized PMP22 expression level, and the value of 
DMSO sample was used for fold change. n=3 to 4 per condition.* p<0.05, 
** p<0.01, one-way ANOVA. Protein expression data displayed as mean 
+/- SD of cytokine dot array intensity. n=4 per condition. ** p<0.01, one-
way ANOVA.  B. Expression level of PMP22 transcript of Schwann cells of 
CMT1A hiPSC lines upon three compound treatments. Data expressed as 
mean +/- SD of normalized PMP22 expression level, and the value of the 
DMSO sample was used for normalization. n=3 to 4 per condition.* 




Table 4-1: Summary of all genotypes included in this study 




GM05148 CMT1A Coriell 17 hiPSC, iNC 
GM05165 CMT1A Coriell 51 hiPSC, iNC 
GM05167 CMT1A Coriell 28 hiPSC 
GM05146 CMT1A Coriell 40 iNC 
HUES PGD 11 CMT1A NIH Stem cell 
registry 
n/a PGD-hESC 
HUES PGD 12 CMT1A NIH Stem cell 
registry 
n/a PGD-hESC 
GM01582 Control Coriell 11 hiPSC 
GM02623 Control Coriell 61 hiPSC 
GM00498 Control Coriell 3 iNC 
GM05756 Control Coriell 2 months iNC 












 Here we report use of CMT1A PGD-hESC Schwann cells and CMT1A iNC-
Schwann cells to validate a phenotype previously found in CMT1A hiPSC-Schwann 
cells.  In total six independent CMT1A genotypes and five control genotypes were 
profiled across three platforms (Table 4-1).  Use of six independent genotypes and 
three methodological platforms increases the robustness of our study methodology 
and provides a model for future disease modeling studies as well. 
Consistent features found across all three Schwann cell models include 
upregulation of the gene PMP22, which is duplicated in CMT1A patients.  PMP22 
upregulation in CMT1A Schwann cells was anticipated but not with complete 
certainty, as most previous reports of PMP22 upregulation in CMT1A patient 
samples were performed on nerve biopsies consisting of a mixture of Schwann 
cells, neurons, fibroblasts, and other cell types13,15, and only one such study was 
performed on cultured CMT1A patient Schwann cells14.  Because PMP22 is also 
known to be expressed in Schwann cells, neurons, and fibroblasts, nerve biopsy 
studies cannot identify which of these cell types are responsible for the increased 
PMP22 expression.  Our study of CMT1A Schwann cells confirms that Schwann cells 
are certainly one of the cell types that upregulates PMP22, and given that CMT1A is 
a dysmyelination and demyelination disorder, Schwann cells are likely the most 
important contributor to CMT1A pathogenesis.  Our study does leave open the 
possibility that CMT1A neurons or fibroblasts may also upregulate PMP22, which 




derived neurons and CMT1A patient primary fibroblasts, both of which are readily 
available to the lab. 
    Our study also demonstrates upregulation of the heparan sulfate 3-O-
sulfotransferase gene, HS3ST3B1 in two of the three models of CMT1A (hiPSCs and 
iNC-Schwann cells).  In the CMT1A PGD-hESC model, HS3ST3B1 is non-statistically 
significantly upregulated, and perhaps a larger sample size would better clarify 
whether the gene is also differentially expressed in that system. 3-O-
sulfotransferases help create the fine structures of heparan sulfate through 
sulfation at a 3-OH.  The sulfation pattern in turn determines the affinity of heparan 
sulftate for various growth factors and ligands, which ultimately allows heparan 
sulfate to regulate a myriad of biological activities from cell growth, differentiation, 
coagulation, etc.  As 3-O-sulfotransferase activity believed to be both rare and rate-
limiting, the upregulation of HS3ST3B1 in CMT1A Schwann cells is likely to be 
biologically meaningful.  Studies in other systems have demonstrated that 
HS3ST3B1 plays a role in mediating Herpes simplex virus-1 cell entry124, epithelial 
mesenchymal transition in pancreatic cancer149, and dementia development in 
HIV133.  The specific physiological role of HS3ST3B1 in Schwann cells, as in most 
other tissues, is currently unknown and presents another opportunity for an 
interesting follow-up study.   
 Inflammatory protein expression profiling of our three congruent CMT1A 
Schwann cell models reveal a converged phenotype. In addition to PMP22 
upregulation, several inflammatory proteins were upregulated in three independent 




overexpressed (Fig.4-8A). CXCL1 has been shown to mediate both neutrophil100–103 
and more recently monocyte104 chemotaxis in various contexts, and has never been 
previously implicated in CMT1A pathogenesis.  MCP-1, also known as macrophage 
chemoattractant protein-1, is one of the best studied chemokines and has been 
shown to robustly induce monocyte migration in a concentration dependent 
manner120,122.  While MCP-1 has never previously been reported as upregulated in 
CMT1A clinical samples, one group has shown its upregulation in a rodent model of 
CMT1A22,23, lending support to our findings.   
Whereas hiPSC model data is conventionally validated through genetic 
correction, the great magnitude of the 1.4Mbp CMT1A duplication makes it 
challenging to edit CMT1A hiPSCs using currently available genome editing 
technology.  Additionally, another disorder, Hereditary Neuropathy with liability to 
Pressure Palsies (HNPP), results in patients with only 1 copy of this 1.4Mbp region. 
Consequently, inadvertent deletion of two copies of the CMT1A duplicated region 
would model HNPP rather than healthy controls, making the lack of control over 
copy number editing with CRISPR/Cas9 an additional concern. To circumvent the 
issues regarding CRISPR/Cas9 editing in the context of CMT1A, CMT1A hiPSC data 
was validated with two independent models, the PGD-hESC- and iNC-Schwann 
cells. The resultant CMT1A-specific Schwann cells exhibit phenotypes consistent 
with those from our CMT1A-hiPSC lines, as well as with nerve biopsy samples from 
genetically diagnosed CMT1A patients. 
Our novel defined protocol for the directed differentiation and prospective 




based activation/inhibition of developmentally relevant pathways to enable 
Schwann cell fate specification in a relatively fast (21-23 days) and efficient 
(13.62% +/- 1.89 in hESCs, 13.56% +/- 0.8817 in control hiPSCs) manner. The 
FACS purified cells can also be subsequently replated, allowing for the study of 
Schwann cell intrinsic properties as well as the potential for in vitro maturation 
along the Schwann cell lineage via extended culture times. Primary human 
Schwann cells are known for their low myelination efficiency in experimental 
settings88, particularly compared to rodent Schwann cells and human 
oligodendrocytes. Considering that our CD49d+ cells robustly express GPR12676–78, 
a gene critical for initiation of myelination, continued myelination studies should 
yield positive outcomes under in vitro and in vivo settings. Given that 
dysmyelination involves impaired myelination by developmentally immature 
Schwann cells, and has been demonstrated to play an important role in several 
CMT1A rodent models19,150, our CMT1A Schwann cells should comprise a reliable 
model for investigating CMT1A pathophysiology during early developmental stages. 
CMT1A is not clinically considered to be an inflammatory disorder, although 
there is some laboratory evidence to support this idea22,23,118,119, in addition to our 
own finding that nerve biopsies from two CMT1A patients upregulate MCP-1 and 
CXCL1 proteins. Our data might suggest that neutrophils or monocytes can be 
recruited to nerves of CMT1A patients, potentially in a CXCL1 and MCP-1 mediated 
manner, as was shown in transwell THP-1 migration experiments. This idea can be 
corroborated by rodent studies, which have found that CMT1A mouse models 
overexpressing or mutating PMP22 have increased macrophage infiltration in 




 Theories of CMT1A pathogenesis often hypothesize Schwann cell growth and 
maturation deficits as being responsible for the dysmyelination and demyelination 
seen in the disorder14,152–154.  This stems from PMP22’s alternate role as a growth 
arrest gene in fibroblasts155,156.  However, our own expression profiling of CMT1A-
hiPSC-derived Schwann cells in Chapter 3 revealed a robust inflammatory 
dysregulation, which was then validated using CMT1A PGD-hESC- and CMT1A iNC-
Schwann cells in this chapter.  Our data suggests that dysregulated immune 
signaling is not only present in CMT1A Schwann cells, but may also comprise an 
early and intrinsic feature of CMT1A Schwann cells.  It is an early feature because 
our Schwann cells are likely of the Schwann cell precursor stage, and it is an 
intrinsic feature because our FACS purification system lends a pure Schwann cell 
culture.   
In addition to modeling disease pathogenesis, our CMT1A Schwann cells can 
also be used to assess drug efficacy, potentially in a patient-specific manner.  
Previous rodent model studies have suggested three candidate drugs for the 
treatment of CMT1A, including ascorbic acid, neurotrophin-3 and progesterone 
antagonists, yet these drugs either have not appeared successful or their effects 
are largely unknown in clinical trials27,29–33,157. Led by a patient advocacy group, the 
CMT Association, there has been a renewed effort to identify drugs that can 
decrease PMP22 mRNA expression level using a rat Schwann cell line148. Such a 
drug discovery campaign may benefit significantly from performing screens in 
human CMT1A Schwann cells as well as using them to validate the effects of hit 
compounds. Although future studies will be required to understand detailed action 




bortezomib reduced PMP22 transcript expression in hiPSCs derived from one patient 
(GM05167) but not another (GM05165), indicate that there might be genotype-
specific drug effects, suggesting that drug validation with individualized human 
Schwann cells may be particularly beneficial for CMT1A patients.  
In addition to the pathological findings, this study also makes paradigmatic 
contributions to the stem cell field. In contrast to conventional validation methods 
which require genome editing to demonstrate reproducibility of a given phenotype, 
here we utilize all three reprogrammed cellular models available to the stem cell 
community to demonstrate a consistent disease phenotype.  Induced pluripotent 
stem cells have already been widely adopted for disease modeling, and direct 
conversion of fibroblasts to target cell types is becoming increasingly embraced as 
more protocols for target cell type induction are being generated.  Use of 
preimplantation genetic diagnosis embryos for disease modeling is also becoming 
progressively feasible as regulatory burdens are clarified and more lines are added 
to the NIH Human Embryonic Stem Cell Registry.  By taking advantage of the 
plasticity of cellular identity through multiple reprogramming approaches, our 
results present an alternative method by which future hiPSC-based studies may 






 In this study, Chapter 3 results from profiling CMT1A hiPSC-Schwann cells 
were validated using CMT1A PGD-hESC-Schwann cells and CMT1A iNC-Schwann 
cells.  Common and novel phenotypes found were upregulation of CMT1A duplicated 
region gene HS3ST3B1 in two of the three models, which plays a rate limiting role 
in heparan sulfate fine structure biosynthesis, and whose specific role in Schwann 
cells is yet to be determined.  In addition, several inflammatory genes and proteins 
were upregulated in all three CMT1A models, and CXCL1 and MCP-1 were ultimately 
commonly overexpressed in all three models, and also found to be upregulated in 
CMT1A patient nerve biopsies.  Transwell assay experiments support the idea that 
THP-1 human monocytes are more readily recruited to CMT1A Schwann cells than 
controls, in an MCP-1 dependent manner.  These results imply dysregulated 
immune signaling may be an intrinsic and early property of nascent Schwann cells, 
and that immune dysregulation may be an early contributor to CMT1A 
pathogenesis, as opposed to a secondary reaction.  Finally, the broadest 
contribution of this study is a methodological one, in which all three reprogrammed 
Schwann cell models were utilized to demonstrate a converged phenotype.  This 
approach offers a technical alternative to genome editing for disease hiPSC 











Wrapping it all up: From PMP22 to Dysmyelination and Demyelination 
CMT1A: More than just PMP22? 
 The 1.4MB CMT1A microduplication is flanked by two 24bp CMT1A-REP 
elements.  Meiotic misalignment of the CMT1-REP elements leads to unequal 
crossing over and the formation of either a microduplication (causing CMT1A) or 
microdeletion (causing HNPP)158–160.   There is even evidence suggesting that this 
locus may be a hotspot for such recombination events159, but there is also a study 
disputing its hotspot status158.   
PMP22 is accepted to be the causal gene in CMT1A, yet there are many other 
genes present in the CMT1A duplicated region which may also contribute to CMT1A 
pathogenesis.  As described in Chapter 1, in addition to PMP22 the region includes 
six known genes, 13 predicted genes, at least a dozen long non-coding RNAs, a 
microRNA, and several pseudogenes12 (Fig. 3-1B).  Our microarray analysis in 
Chapter 3 was able to evaluate the presence of some of these genes, and found 
both PMP22 and HS3ST3B1 to be upregulated in CMT1A hiPSC-Schwann cells.  The 
HS3ST3B1 gene was also found to be significantly upregulated in CMT1A iNC-
Schwann cells, and non-significantly upregulated in CMT1A PGD-hESC-Schwann 
cells, likely due to the small sample number included in that study.   
To our knowledge, this is the first report that a non-PMP22 gene from the 
CMT1A duplicated region has been aberrantly expressed in CMT1A Schwann cells.  
Because of the rate limiting role HS3ST3B1 plays in heparan sulfate fine structure 
modification and the important regulatory roles heparan sulfate fine structures can 




important.  Plans are in place to evaluate effects of HS3ST3B1 by transfecting 
control hiPSC- and ES-Schwann cells with PMP22 +/- HS3ST3B1 and determining 
whether any inflammatory genes are subsequently upregulated.   
To evaluate the role of the many non-PMP22 genes from the CMT1A 
duplicated region that were not included in our microarray panel, it would be very 
interesting to use RNA sequencing to assess their expression levels in CMT1A 
patient-derived Schwann cells vs controls.  Given a large enough collection of 
patient samples and complete data on their clinical characteristics, it might even be 
possible to correlate expression of some non-PMP22 genes to clinical outcomes.  
There is great variability in the clinical manifestations of CMT1A, and they do not 
particularly correlate with PMP22 expression levels13,15.  The idea of interrogating 
the role of these other genes in a patient-specific manner is an exciting follow-up 
application of the platform we’ve developed. 
Elucidating a mechanism: CXCL1 and MCP-1 in Schwann cells  
Our findings add CXCL1 and MCP-1 secretion by CMT1A Schwann cells to an 
increasing body of work on Schwann cell immunocompetence, as outlined in 
Chapter 1.  Here we hypothesize possible consequences of CXCL1 and MCP-1 
upregulation in the context of CMT1A. 
CXCL1 is a potent chemokine well-known for its role in neutrophil 
chemotaxis.  Secretion of CXCL1 by pathological cell types and its subsequent 
binding to the CXCR2 receptor on neutrophils induces neutrophil chemotaxis and 
appears to mediate inflammatory damage in a number of diseases including Lyme 




suggesting CXCL1 can also act as a monocyte chemoattractant104.  It is reasonable 
that CXCL1 may be playing a similar role in CMT1A patient Schwann cells/Schwann 
cell precursors.   
In addition, CXCL1 has been reported to have an analgesic effect relieving 
inflammatory pain in the nervous system161.   Leukocytes containing opioid peptides 
such as B-endorphin, met-enkephalin, dynorphin, and endomorphins enter inflamed 
peripheral nerves and release opioid peptides in response to certain environmental 
signals162.  Specifically, soluble CXCL1 released by inflamed tissues can bind CXCR2 
receptors on opioid-containing granulocytes and induce their migration into 
inflamed tissues as well as their subsequent degranulation161.   
This suggests a model in which CMT1A Schwann cell-secreted CXCL1 may 
induce neutrophil migration into the peripheral nerve; there the neutrophils may 
play one of two potential roles, one pathogenic and one analgesic.  Upon 
chemotaxis and degranulation some neutrophils may release myeloperoxidase, 
alkaline phosphatase, lactoferrin, lysozyme, and NADPH oxidase, mediating 
cytotoxic damage to the nascent nerve and contributing to CMT1A pathogenesis.  
Another population of neutrophils may release endorphins and other opioid peptides 
upon degranulation, providing local analgesia in the inflamed nerve.  Alternatively, 
it is altogether possible that CXCL1 does not mediate neutrophil chemotaxis in the 
context of CMT1A, and rather performs an as of yet uncharacterized role in immune 
signaling or perhaps even developmental signaling. 
In addition to CXCL1, our data also demonstrates that CMT1A patient 




Chemoattractant Protein 1, one of the most extensively studied chemokines.  MCP-
1 robustly induces circulating monocytes to exit the bloodstream and enter foci of 
active inflammation in the tissues.  MCP-1 exerts its effects through signaling to its 
cognate receptor, CCR2.  Whereas MCP-1 can be expressed by a variety of cell 
types (monocytes, macrophages, endothelium, fibroblasts, epithelium, neurons, 
microglia, Schwann cells, and others), expression of CCR2 is restricted to 
monocytes, activated T cells, and dendritic cells120.   
MCP-1 has been previously shown to mediate inflammation in a number of 
neurological diseases including multiple sclerosis, stroke, and Alzheimer’s disease.  
MCP-1 is upregulated in the macrophages and astrocytes of acute plaques of 
multiple sclerosis patients, but attenuates somewhat in chronic MS plaques120.  In 
stroke, MCP-1 expression in the post-ischemic brain and is thought to be an early 
inducer of leukocyte migration and these leukocytes appear to contribute to 
subsequent post-ischemic injury.  Interestingly, overexpression of MCP-1 in rodents 
appears to increase infarct volume whereas knocking out MCP-1 seems to be 
neuroprotective during ischemia120.  In Alzheimer’s disease, amyloid-beta activates 
astrocytes to secrete MCP-1, which then attract microglia.  In addition, 
microvessels of Alzheimer’s patients appear to upregulate endothelial expression of 
MCP-1163, and in another study, MCP-1 and other chemokines in combination with 
amyloid-beta were able to induce monocyte migration across a human model of the 
blood brain barrier164.  These studies demonstrate that not only is MCP-1 
upregulated in several neurological disorders, but it may also be able to alter the 




Similar to the CNS, MCP-1 has been repeatedly implicated in 
neurodegeneration in the PNS40,55,121,165.   It appears that during PNS Wallerian 
degeneration, neuronal injury40 and Schwann cell denervation121 results in Schwann 
cells upregulating MCP-1 and other chemokines that lead to macrophage 
infiltration.  In the context of axotomy, macrophage recruitment is often adaptive, 
as it facilitates clearance of myelin debris and allows for axonal regeneration. 
MCP-1 upregulation in multiple sclerosis, stroke, Alzheimer’s disease, and 
PNS Wallerian degeneration consistently appears to be a secondary response to a 
primary pathology (ie acute MS plaque formation, ischemia, amyloid-beta 
overexpression, and axotomy).  In our CMT1A Schwann cells, on the other hand, 
MCP-1 secretion occurs even in the absence of any injury, as our Schwann cells 
haven’t even had the chance to form myelin yet.  Our results further the idea that 
MCP-1 upregulation by Schwann cells may play an early role in CMT1A 
dysmyelination and demyelination, possibly through monocyte/macrophage 
recruitment or through yet undefined mechanisms.   
The idea that MCP-1 upregulation/macrophage recruitment may be 
degenerative rather than adaptive in the context of CMT1A patients is supported 
from data from Rudolf Martini’s mouse model of CMT1A.  In this model, which 
expresses four copies of human PMP22, macrophages were found to be elevated in 
CMT1A mouse nerves23.  Interestingly, knocking out one or both copies of MCP-1 
decreased macrophage infiltration, ameliorated demyelination, and improved grip 
strength22.  Whereas the Martini group interprets CMT1A as being a primarily 




cell precursor stage suggests that MCP-1 may even be contributing to 
dysmyelination, prior to the onset of demyelination. 
 Thus far, we have interpreted the CXCL1 and MCP-1 upregulation seen in our 
CMT1A Schwann cells as playing an immunopathologic role in CMT1A pathogenesis, 
as supported by our transwell assay results and other groups’ data from CMT1A 
rodent studies.  However, it should be noted that CXCL1 and MCP-1 may have 
alternate functions in the context of CMT1A, perhaps through modulating 
developmental signaling cascades, migratory signals, or other yet to be defined 
biological processes, as many cytokines are now being found to play diverse and 
varied roles when expressed within the nervous system166,167. 
Reconciling major theories of CMT1A pathogenesis 
While there are many theories of how PMP22 overexpression causes CMT1A, 
CMT1A is not clinically considered to be an inflammatory disorder.  One major 
model of CMT1A pathogenesis asserts that PMP22 duplication alters Schwann cell 
proliferation, differentiation, or apoptosis.  Schwann cell proliferation and 
differentiation are inherently linked as the pro-myelinating Schwann cell can 
proliferate but has not yet initiated myelination.  Upon differentiation to a 
myelinating Schwann cell, it must exit the cell cycle.  Whether PMP22 
overexpression increases or decreases CMT1A Schwann cell proliferation appears to 
vary based on the experimental context.  In general, it appears that PMP22 
overexpression increases Schwann cell proliferation in in vivo rodent models, but 
decreases Schwann cell proliferation in both in vitro Schwann cell cultures and in 




and control patient-derived hiPSC/PGD-hESC/iNC-Schwann cells, there were no 
observed differences in proliferation rates, though more precise analyses should be 
performed going forward. 
Another major theory of CMT1A pathogenesis is that aberrant PMP22 folding 
or trafficking is responsible.  As a membrane protein, PMP22 must be trafficked 
from the endoplasmic reticulum to the plasma membrane.  Point mutations in the 
PMP22 gene, such as those found in some CMT1A patients and the Trembler 
mouse, result in misfolding of PMP22 protein and impaired trafficking from the 
ER/Golgi to the membrane169.  In addition to PMP22 point mutations leading to 
misfolding, it appears that wt PMP22 overexpression can also result in misfolding, 
as demonstrated in the C22 mouse that harbors 7 copies of PMP22118.  In the 
context of PMP22 duplications, it appears that overexpressing PMP22 may also 
overwhelm the ubiquitin-proteosome pathway and result in cytoplasmic PMP22 
aggregation and activation of autophagosomes and lysosomes.  Cytoplasmic PMP22 
aggregates decrease the amount of PMP22 that can be targeted to the membrane 
and can lead to the downstream myelination deficits170–172. 
A less widely reported theory of CMT1A pathogenesis is that CMT1A (or 
CMT1, in general) has a substantial inflammatory component.  Most of the data 
supporting this idea have come from Rudolf Martini’s mouse models of CMT1A, 
CMT1B, and CMT1X, and some supporting evidence has come from Lucia 
Notterpek’s mouse models of CMT1A.  As mentioned earlier, the Martini lab’s C61 
mouse model of CMT1A (4 copies of PMP22) exhibits increased macrophage 




substantially decreases the macrophage infiltration and improves myelination23,117.  
Similarly, in their mouse models of CMT1B (P0 +/-) and CMT1X (Cx32 -/-) they see 
almost normal myelin formation followed by slowly progressing demyelination, with 
association of T-cells and macrophages in the nerves of the CMT1B and CMT1X 
mice151,173.  Common themes across all three of their models were that 
macrophages were found in contact with myelin sheathes or axons, suggesting that 
macrophages play an active role in CMT1 demyelination.  Similarly, the Notterpek 
group’s C22 (7 copies of PMP22) and Trembler-J (PMP22 point mutation) mouse 
models of CMT1A both exhibited increased CD11b-positive macrophages infiltration 
in sciatic nerves, further validating this finding of increased inflammation in two 
additional models of CMT1A. 
Our results that the CMT1A patient hiPSC/PGD-hESC/iNC Schwann cells 
upregulate CXCL1 and MCP-1 best support an inflammatory model of CMT1A 
pathogenesis.  Although this finding has already been validated in nerve biopsies 
from two CMT1A patients, a significant finding, more thorough validation efforts 
must be performed going forward to better determine the role of dysregulated 
immune signaling in CMT1A.  This should be done initially through profiling a 
broader number of nerve biopsies from CMT1A and control patients for CXCL1 and 
MCP-1 expression.  In addition to evaluating expression of these proteins, it would 
also be useful to histologically examine macrophage or leukocyte infiltration, and 
determine whether there are even subtle differences relative to controls.  
Furthermore, it might also be interesting to determine whether immunomodulatory 




through corticosteroid administration to CMT1A rodents at various time points from 
birth to adulthood.   
There do exist several case reports of CMT1A patients who benefitted from 
corticosteroid therapy, yet they are generally diagnosed as having an acquired 
neuropathy superimposed onto a hereditary one174–177.  Our data implores asking 
whether inflammation in CMT1A may actually be more common than these 
occasional case reports would otherwise suggest.  Ultimately, if our findings are 
corroborated in other settings, it might blur the conventional clinical line between 
acquired demyelinating neuropathies (ie GBS and CIDP) which are thought to be 
inflammatory, and the hereditary dys- and demyelinating neuropathies which are 






Future applications of patient-derived Schwann cells 
Modeling hereditary and acquired Schwann cell disorders 
In this series of studies, we report the successful engineering of patient-
derived Schwann cells from three different sources.  Fibroblasts were have been de-
differentiated in hiPSCs and re-differentiated into Schwann cells, to make CMT1A 
hiPSC-derived Schwann cells.  Embryonic stem cell lines were cultured from 
blastocysts with the CMT1A duplication and subsequently differentiated into 
Schwann cells.  Fibroblasts were also directly converted into Schwann cells, 
bypassing the pluripotent stem cell stage.   
The three methods of reprogrammed Schwann cell derivation were used in 
this study to model CMT1A, but going forward they can be used to model a number 
of disorders.  As reviewed in Chapter 1, there are many genetic Schwann cell 
disorders that might potentially benefit from disease modeling with our platform, 
including numerous subtypes of CMT1, Hereditary Neuropathy with Liability to 
Pressure Palsies (HNPP), Dejerine-Sottas disease, Schwannomatosis, and perhaps 
vestibular schwannomas of Neurofibromatosis Type II (NF2).  In all of these 
disorders, there are still open questions of how associated genetic mutations cause 
the pathology observed clinically, and modeling them using patient-derived samples 
will likely add new insights.   
In addition to modeling hereditary Schwann cell disorders, it may also be 
possible to adapt our platform for the modeling of acquired Schwann cell disorders 
(ie GBS and CIDP).  For instance, we may readily collect skin fibroblasts from GBS 




Schwann cells.  Gene expression profiling of GBS/CIDP patient hiPSC or iNC-derived 
Schwann cells could allow us to better understand their molecular pathology 
without performing invasive nerve biopsies.  Co-culturing patient hiPSC or iNC-
derived Schwann cells with T-cells from peripheral blood of the same patient may 
also lead to some novel insights.  For instance, comparing interactions between 
different combinations of Schwann cells and T-cells from GBS patients and healthy 
controls might help shed light on how much pathology is Schwann cell-intrinsic vs 
T-cell-intrinsic.   
Broadening the spectrum further, our patient hiPSC- or iNC-derived Schwann 
cells might also be used for modeling leukodystrophies that affect both the CNS and 
PNS, like Krabbe disease178.  Similar molecular pathology may be present in both 
the affect Schwann cells and oligodendrocytes in these disorders.  Because many 
other groups have developed methods for hiPSC differentiation into 
oligodendrocytes and direct conversion towards oligodendrocytes139,179, engineered 
Schwann cells and oligodendrocytes could be generated from Krabbe patient cells 
and profiled for common molecular pathologies.   
Drug screening 
 In addition to disease modeling, our three methods of patient-derived 
Schwann cell development can also be utilized for drug screening.  Our hiPSC-
Schwann cell and PGD-hESC-Schwann cell differentiation protocols in particular 
yield Schwann cells that can be expanded in culture for up to two months, making 
them particularly well suited for high throughput drug screening (HTS).  Currently, 




cancer cell lines, which may not share the same characteristics of the tissues 
involved in disease pathogenesis.  Consequently, patient-derived engineered 
Schwann cells likely better mimic the endogenous diseased Schwann cells and likely 
have better predictive efficacy in high throughput screens.  In this study, we used 
our CMT1A hiPSC-derived Schwann cells to evaluate the effect of three drugs 
(bortezomib, fenretinide, and olvanil148) on PMP22 expression on hiPSCs derived 
from two different patients.  Expanding this study to include more hiPSC clones and 
lines representing a broader number of CMT1A and control genotypes could help 
better establish the effect these three drugs play on PMP22 gene expression or 
CXCL1 and MCP-1 protein expression, particularly as they are evaluated in pre-
clinical trials.   
Cell transplantation therapy 
 Though still quite distant, therapeutic transplantation of stem cell-derived 
cells is one of the most highly anticipated applications of stem cell technology.  Our 
system yields three different sources of patient-derived Schwann cells that could 
potentially be used for transplantation therapy in the future.  The advantage of 
hiPSC-Schwann cells and iNC-Schwann cells is that they can be derived from a 
patient’s own fibroblasts, thereby minimizing immunocompatability concerns.  An 
advantage of hiPSC-Schwann cells and PGD-hESC-Schwann cells is that they can be 
expanded in vitro prior to transplantation, thereby yielding larger cell numbers.  
And a major advantage of iNC-Schwann cells is that, by bypassing the pluripotent 
stem cell stage, these cells have lower tumorigenic potential than their hiPSC and 




 There are a number of disorders that might potentially benefit from Schwann 
cell transplantation one day.  In a collaboration with Gerald Brandacher’s group we 
are currently evaluating whether transplantation of control hiPSC-derived Schwann 
cells affects functional neuro-regeneration in rodent models of chronic denervation 
and limb transplantation surgery.  Clinically, in the context of hereditary 
neuropathies like CMTs, transplantation of patient-matched, genetically corrected 
Schwann cells to treat demyelination is certainly appealing.  Similarly, patient-
matched Schwann cell transplantation might also be worth investigating in acquired 
inflammatory neuropathies (ie GBS and CIDP) and even in spinal cord injury, as 
Schwann cell transplantation into the spinal cord may aid re-myelination and axonal 





 As an MD/PhD student, it is currently an exciting time embark on a career as 
a physician-scientist.  Recent advances in stem cell technology in particular make 
bedside-to-bench experiments readily accessible, and with time, I hope to also 
translate my findings from the bench back to the bedside.  Our lab has created 
three exciting “disease in a dish” platforms—two of which were the result of this 
dissertation—to better understand Schwann cell disease biology, screen for drugs, 
and potentially transplant therapeutically.  As I progress through my anticipated 
career as an academic neurologist, I hope to build upon the techniques learned and 
knowledge acquired during this dissertation to continue to contribute to our 
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Derivation of Schwann cells has enormous implications for the study of peripheral 
neuropathies. Here we describe a defined method to directly differentiation human 
pluripotent stem cells into Schwann cells, followed by antibody based FACS 






2.1 Equipment  
1. Cell culture disposables: Cell culture dishes, multiwell plates, centrifuge 
tubes, pipettes, pipette tips, sterile filter units.  
2. Nylon mesh cell strainers, 45 µm pore size (BD Falcon, cat. no. 352340). 
3. Glass Pasteur pipettes, sterilized by autoclaving and dry heat monitored with 
indicator tape. 
4. Bench-top laminar flow hood with a HEPA filter.  
5. Inverted microscope. 
6. Picking hood. 
7. Dissecting microscope. 
8. CO2 incubator with CO2, humidity, and temperature control. 
9. Cell culture centrifuge.  
10.Glass hemocytometer. 
 
2.2 hPSC culture 
1. Human embryonic stem cells or induced pluripotent stem cells (see Note 1) 
2. MEF CF-1 mitomycin-C treated mouse embryonic fibroblasts (MEFs; Applied 
StemCell, Inc., ASF-1223).  
3. MEF medium containing 900 mL of Dulbecco’s modified Eagle medium (Life 
Technologies, cat. no. 11965-118), 100 mL fetal bovine serum (Life 
Technologies, cat. no. 26140-095). The medium is sterile-filtered before use.  




stock in 1x DPBS containing 0.1% BSA (see Note 2 about growth factors).  
5.    hESC medium containing 800 mL of DMEM/F12 hESC medium  (Life 
Technologies, cat. no. 11330-032), 200 mL knockout serum replacement 
(KSR; Life Technologies, cat. no. 10828-028), 5 mL L-glutamine (200 mM, 
Life Technologies, cat. no. 25030-081), 10 mL MEM non-essential amino 
acids (MEM NEAA; Life Technologies, cat. no. 11140-050), and 1 mL of 2-
mercaptoethanol (Life Technologies, cat. no. 21985-023).  The medium is 
sterile filtered in a hood and 60 ul of FGF2 stock is added after filtration to a 
final concentration of 6 ng/mL.  
6.   Sterile 1x DPBS (Gibco/Life Technologies, cat. no. 14190) 
7. Gelatin coated dishes made by adding enough gelatin to coat the bottom of 
the dish (0.1% gelatin in PBS, Chemicon/Millipore, cat. no. ES-006-B). Allow 
gelatin to incubate for at least 15 minutes prior to plating cells. Remove 
gelatin before plating. 
8. Dispase (5U/ml, Stem Cell Technologies, cat. no. 07913)  
9. MEF conditioned medium (CM) is harvested from MEF coated flasks.  MEFs 
are plated at a density of 50,000 cells/cm2 in a T225 flask in MEF medium.  
The next day, the cells are washed once with PBS before adding 100 mL of 
hESC medium.  Incubate medium with MEFs for 24 hours before removal. 
The medium is now known as “conditioned medium” (CM) and can be directly 
used or stored at 4˚C for less than two weeks. Additional hESC medium can 
be conditioned daily for up to ten days on the same flask of feeders.  Just 
before using, FGF2 is added to CM to a final concentration of 10 ng/mL, 





2.3 Schwann cell differentiation  
1. Accutase (Innovative Cell Technologies, cat. no. AT104) 
2. Nylon mesh cell strainers, 45 µm pore size (BD Falcon, cat. no. 352340) 
3. Matrigel Basement Membrane Matrix (BD Bioscience; cat. no. 354234: we 
only use lots that contain over 10 mg/ml protein). Thaw the frozen vial of 
Matrigel on ice overnight in a 4˚C refrigerator.  Prepare 1 mL aliquots in a 
50 mL centrifuge tube using chilled pipettes and freeze at -20˚C. Matrigel 
must be thawed slowly to prevent gelatinization.  Chilled pipettes and 50 mL 
centrifuge tubes should be used when making aliquots of the Matrigel. 
4. KSR medium, containing 820 mL of Knockout DMEM (Life Technologies; cat. 
no. 10829-018), 150 mL KSR (Life Technologies, cat. no. 10828-028), 10 
mL L-glutamine (200 mM, Life Technologies, cat. no. 25030-081), 10 mL 
MEM NEAA (Life Technologies, cat. no. 11140-050), and 1 mL of 2-
mercaptoethanol (Life Technologies, cat. no. 21985-023).  
5.   NB medium, containing 1000 mL of Neurobasal medium (Life Technologies, 
cat no. 21103-049), 10 mL L-glutamine (Life Technologies, cat. no. 25030-
081), 20 mL B27 supplement (Life Technologies, cat. no. 12587-070), and 
10 mL N2 supplement (Life Technologies, cat. no. 17502-048) 
6.    SB-431542 (Tocris Bioscience, cat. no. 1614) prepared at 10 mM in 100% 
ethanol (1000x stock). 
7.    LDN-193189 (Stemgent, cat. no. 04-0074) prepared at 500 uM in DMSO 
(1000x stock). 




mM in sterile water (1000x stock). 
9.    CHIR 99021 (Tocris Bioscience, cat. no. 4423) prepared at 6 mM in DMSO 
(2000x stock). 
10. DAPT (R&D Systems, cat. no. 2634) prepared at 10 mM in DMSO (1000x 
stock.) 
11. Dibutyrl cAMP (Sigma, cat. no. D0627) prepared at 100 mM in sterile water 
(500x stock). 
12. Sodium L-ascorbate (Sigma, cat. no. A4034) prepared at 100 mM in sterile 
water (500x stock). 
2.4 Schwann cell purification and culture 
13. 1mg/ml mouse laminin I solution (LAM; Cultrex, R&D Systems, cat. no. 
3400-010-1, 1000x stock). 
14. 2mg/ml human fibronectin (FN; R&D Systems, cat. no. 1918-FN-02M, 1000x 
stock) 
15. FN/LAM-coated dishes: Add 1ug/ml LAM and 2ug/mL FN (in PBS) to 12 well 
cell culture plates.  Incubate at least two hours, preferably overnight – 
longer incubation improves adhesion. Before using plates, aspirate medium. 
16. DMEM with 10% FBS, containing 450 mL DMEM high glucose (Life 
Technologies, cat. no. 11965-118) and 50 mL fetal bovine serum (Hyclone, 
cat. no. SH30070.03). 
17. DNase1 (Roche applied science, cat. no. 10104159001) prepared at 10 
mg/mL in sterile water.  
18. FACS buffer, containing 40 mL DPBS (Corning, cat. no. 21-031-CV), 10 mL 




19. Human Integrin alpha 4/CD49d Phycoerythrin MAb (Clone 7.2R) (R&D 
Systems, cat. no. FAB1354P). 
20. NB medium with 1% FBS, containing 49.5 mL NB medium and 0.5 mL fetal 
bovine serum (Hyclone, cat. no. SH30070.03). 
21. Trypsin EDTA, 0.25% (Life Technlogies, 25200-114) 
 
3. Methods 
3.1 Grooming and preparation of hPSCs for differentiation 
1. Groom pluripotent cells (hESCs or hiPSCs) using the picking hood, objective 
microscope and 200 µL pipette with sterile filter tips.  Remove any 
pluripotent colonies that have the appearance of differentiated cells, 
irregular borders, or transparent centers. 
2.     Aspirate hESC medium and add minimal Accutase to coat the dish and let 
sit at 37°C until all colonies are rendered to single cells (approximately 20 
minutes). Amount used: 1 ml for a 6 well dish, 2 ml for a 6 cm dish, or 5 ml 
for a 10 cm dish. 
3.     Avoiding bubbles, triturate the cells in the dish using a pipette with 
additional  
nylon cell strainer to remove clumps.   
4.     Wash and centrifuge cells (200 x g for 5 minutes) twice in hESC medium 
to remove all traces of Accutase.  




to the frozen Matrigel aliquot (see equipment setup) and pipette until 
thawed. Work quickly and do not let the Matrigel warm up or it will 
polymerize.  A 45 µm nylon cell strainer can be used to remove any 
insoluble clumps. Coat 24 well cell culture plates with the diluted Matrigel 
solution and incubate for 1 hour at 37 degrees Celsius.   
6.     After washing hPSCs, resuspend the cells in hESC medium containing 10 
µM Y-27632 and plate on a gelatin-coated dish 2-3x the area as step 2 (e.g. 
10 cm gelatin-coated dish for a 6 cm dish of Accutase treated cells). (Y-
27632 prevents single hPSCs from dying) 
7.     Incubate dish at 37˚C for 30 minutes in a cell incubator.   
8.     After 30 minutes, collect the non-adherent cells and wash the dish with 
hESC medium containing 10 µM Y-27632 and centrifuge cells.  
9.     Resuspend the cells in cCM + 10 µM Y-27632.  
10. Determine the cell concentration using a hemocytometer and add cCM + 10 
µM Y-27632 to the appropriate cell volume to achieve 70,000 to 120,000 
cells/well in a 24 well plate.  
11. Aspirate Matrigel solution. 
12. Plate pluripotent cells on Matrigel-coated dishes at 70,000 to 120,000 
cells/well in a 24 well plate.  
13. Twenty-four hours after plating, aspirate medium and add fresh cCM + 10 
µM Y-27632.   
14. Forty-eight hours after plating, aspirate the medium and add fresh cCM – 
from this point on, Y-27632 is no longer necessary.  Cells can be maintained 




(~70%-80% confluence for schwann cell differentiation).  
 
3.2 Schwann cell differentiation 
10.Prepare hPSCs for neural induction as described above in 3.1 and maintain 
until 70-80% confluence is reached. 
11.To initiate differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542 and 500 nM LDN-193189 (day 0).   
12.On day 2 of differentiation, aspirate the medium and add KSR medium 
containing 10 µM SB-431542, 500 nM LDN-193189, 3 µM CHIR 99021, 10 
µM DAPT.  (activates WNT while blocking gamma secretase/Notch) 
13.On day 4 of differentiation, aspirate the medium and add KSR/NB (3:1) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT (final 
concentrations are for the combined KSR/NB mixture). 
14.On day 6 of differentiation, aspirate the medium and add KSR/NB (1:1) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT. 
15.On day 8 of differentiation, aspirate the medium and add KSR/NB (1:3) 
medium containing 3 µM CHIR 99021 and 10 µM DAPT. Some toxicity may 
be observed that is inversely correlated with efficiency of SOX10 induction. 
16.On day 10 of differentiation, aspirate the KSR/NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
17.On day 14 of differentiation, aspirate the NB and add NB medium 
containing 200 µM dibutyrl cAMP and 200 µM sodium L-ascorbate.   
18.On day 18 of differentiation, aspirate the NB and add NB medium 




19.Maintain in this manner until day 21-23 of differentiation, when the cells 
are ready for purification. 
 
3.3 Schwann cell purification using CD49d antibody 
1. Prepare hPSCs for schwann cell induction as described above in 3.1  
2. Aspirate hESC medium and add minimal Accutase with 50 µg/mL DNase1 
to coat the dish and let sit at 37°C until all colonies are rendered to single 
cells (approximately 30 minutes). Amount used: 0.25 mL for each well of a 
24 well plate 
3.  Avoiding bubbles, triturate the cells in the dish using a pipette with 
additional DMEM + 10% FBS medium until there is a single cell 
suspension.  
4. Centrifuge cells (200 x g for 4 minutes) to remove Accutase.  
5. Resuspend cells in FACS buffer to a concentration of approximately 10 
clumps.  Dilute 50 uL of these cells in 500 uL FACS buffer to serve as an 
unstained control for FACS. 
6. Stain the remaining cells with the CD49d-PE antibody, diluted in a 1:100 
volumentric ratio of antibody to cells.  Incubate on ice, covered from light, 
for 10-15 minutes, tapping occasionally. 
7. Wash the cells with two volumes of FACS buffer, and centrifuge (200 g for 
4 minutes). 





9. Perform FACS and collect CD49d-PE+ (Schwann cell) and CD49d-PE- (non-
Schwann cell) populations. 
10.For culturing of Schwann cells after FACS, two approaches may be 
employed.  Method A:  Use a 2 mL pipet to pipet 50,000 cells into each 
well of a 12 well plate coated in FN/lam.  Add at least 1 mL of NB + 1% 
FBS medium to each well.  Change medium once cells adhere, typically 2-4 
days.  Method B: Centrifuge freshly sorted cells (200 g for 5 min) and 
gently tap to resuspend in NB + 1% FBS.  Plate 50,000 cells into each well 
of a 12 well plate coated in FN/lam.   
11.Passage cultured Schwann cells after several days upon confluency, using 
a 5 min trypsin incubation.  Wash with DMEM + 10% FBS, centrifuge (200 







1. Human pluripotent stem cells differ in their properties, so optimization might 
be required for a cell line of interest. These protocols were primarily derived 
using H9 hESCs although studies have also demonstrated their utility with 
hiPSCs. The plating efficiency, the optimal NC-inducing cell density and the 
concentration and timing of growth factors are all variables that might need 
adjustment to find the best yield for a given pluripotent stem cell source.  
2. We generally purchase growth factors in bulk as lyophilized protein. Most 
factors are reconstituted in 1x DPBS containing 0.1% BSA at a concentration 
recommended by the manufacturer: storing recombinant proteins at too low 
of a concentration promotes instability. We do not sterile filter recombinant 
proteins because protein can adhere to the membrane, lowering the 
effective concentration of the preparation. Single-use aliquots are stored at -














Appendix 2A: Table of qRTPCR Primers used 
Primer name Sequence (5’ to 3’) 
LincROR fwd GCTTAGCGGCTGAAGACTGA 
LincROR rev CTTAGCGACAATGCCATCAA 
HHLA1 fwd AAAGTTTGTTTGGTGGTTTTTT 
HHLA1 rev AAAAAAATTAATCTCCTCCATATACCTT 
S100B fwd AGGGAGACAAGCACAAGCTG 
S100B rev CGTGGCAGGCAGTAGTAACC 
Periostin fwd CTGCCATCACATCGGACATA 
Periostin rev GCGTCTCAAAGACTGCTCCT 
GPR126 fwd CGAATGAGATGCATGTGTCC 
GPR126 rev CTTCATGGCCAACTTTGGTT 
TGFBI fwd GTCCACAGCCATTGACCTT 
TGFBI rev ACCGCTCACTTCCAGAGAGA 
IL1R1 fwd GATTGTGAGCCCAGCTAATGAG 
IL1R1 rev AGCACTGTGATGAGGGTACTCC 
HS3ST3B1 fwd TATTCAGCCTTCAGTCACCGTC 
HS3ST3B1 rev GGTACACAGGCAGGAAGAGACA 
PMP22 fwd CTGGTCTGTGCGTGATGAGT 
PMP22 rev AGATGACACCGCTGAGAAGG 
TNFAIP2 fwd TTCAAGAGGTTCACGCACAC 
TNFAIP2 rev CCCTTGCTGAGTTGGATGAT 
IL-6 fwd GGTACATCCTCGACGGCATCT 
IL-6 rev GTGCCTCTTTGCTGCTTTCAC 
IL-8 fwd ATGACTTCCAAGCTGGCCGT 
IL-8 rev TCCTTGGCAAAACTGCACCT 
CCL2/MCP-1 fwd AGGTGACTGGGGCATTGAT 
CCL2/MCP-1 rev GCCTCCAGCATGAAAGTCTC 
TGFB1 fwd GCCCTGGACACCAACTATTGC 
TGFB1 rev GCTGCACTTGCAGGAGCGCAC 
CXCL12 fwd CTGGGCAAAGCCTAGTGA 
CXCL12 rev GTCCTGAGAGTCCTTTTGCG 
Cxcl1 fwd AACCGAAGTCATAGCCACAC 
Cxcl1 rev GTTGGATTTGTC ACTGTTCAGC 
Cxcl14 fwd GTACCGAGGTCAGGAGCACT 
Cxcl14 rev TTGCACAAGTCTCCCAACTG 
Mip1a/CCL3 fwd ATGCAGGTCTCCACTGCTGCCCTT 
Mip1a/CCL3 rev GCACTCAGCTCCAGGTCGCTGACAT 
CDH19 fwd ATTGGTCAGCCAGGAGCGTTGT 
CDH19 rev GCAGATTCAGAGACAGTCAAGCG 
Sox10 fwd ATACGACACTGTCCCGGCCCTAAA 
Sox10 rev TTCTCCTCTGTCCAGCCTGTTCTC 
DHH fwd AGGATGAGGAGAACAGTGGAGC 




Appendix 2B: Table of primary antibodies used 
Antigen Species Company 
GFP Rabbit Cell Signaling 2956 
GFP Chicken Abcam 13970 
TUJ1 Rabbit Covance MRB-435P 
TUJ1 Mouse Covance MMS-435P 
GFAP Rabbit Pierce PA3-16727 
GFAP Rabbit DAKO Z0334 
S100B Rabbit DAKO Z0311 
GalC Mouse EMD Millipore MAB342 
Nanog Rabbit Cell Signaling 3580 
SSEA3 Rat DSHB MC-631 
SSEA4 Mouse DSHB MC-813-70 
Tra1-60 Mouse Cell Signaling 4746 
Tra1-81 Mouse Cell Signaling 4745 
Periaxin Rabbit Sigma HPA001868 









Birth Date and Place 
 




 Ph.D. Neuroscience Graduate Program, 2011-2015 
Thesis title, “Modeling Charcot Marie Tooth 1A with Human 
Pluripotent Stem Cells” 
 Johns Hopkins University School of Medicine 
Research Advisor:  Gabsang Lee, Assistant Professor of 
Neurology and Neuroscience 
 
 M.D. In progress, 2009-present 
 Johns Hopkins University School of Medicine 
 
 B.A. Molecular and Cell Biology, 2007 
  University of California, Berkeley 
  Emphasis in Biochemistry 
  Minor in BioEngineering 





PhD Candidate Oct 2011-May 2015 
Lab of Gabsang Lee, DVM/PhD, Assistant Professor of Neurology and 
Neuroscience 
 Johns Hopkins University School of Medicine 
 
As part of my dissertation, I first developed a methodology for 
differentiating human embryonic stem cells (hESCs) and human induced 
pluripotent stem cells (hiPSCs) into Schwann cells.  This methodology 
was then applied to the creation of an in vitro model of Charcot Marie 




dysmyelination and demyelination.  Skin fibroblasts from CMT1A patients 
were epigenetically reprogrammed into hiPSCs and subsequently 
differentiated into Schwann cells.  Gene expression profiling and protein 
expression profiling experiments then revealed a very interesting 
phenotype of dysregulated immune signaling, which is not classically 
considered to play a role in CMT1A pathogenesis, but has been reported 
in multiple CMT1A animal models by other investigators.  Results from 
our CMT1A hiPSC-derived Schwann cells were validated using CMT1A 
hESC-derived Schwann cells as well as CMT1A skin fibroblasts that were 
directly converted into Schwann cells without entering a pluripotent 
state.  hiPSCs, hESCs, and direct lineage converted cells represent the 
three models currently available, and this work is notably the first report 
utilizing all three models to demonstrate a consistent phenotype.   
 
PhD Rotation Student Jun 2010 – Aug 2010 
Lab of Michael Caterina, MD/PhD, Professor of Biological Chemistry and 
Neuroscience 
 Johns Hopkins University School of Medicine 
 
I helped investigate the role of TRPV3 in regulating skin inflammation, 
and also explored the role of skin (keratinocytes) in mediating heat 
sensation by trying to determine whether signaling can occur between 
keratinocytes and sensory neurons.    
 
Staff Research Associate/Lab Manager Jun 2007 – May 2009 
 Lab of Robert Edwards, MD, Professor of Neurology and Physiology 
 University of California, San Francisco 
 
Performed functional and structural studies of the synaptic vesicle 
protein, Vesicular Monoamine Transporter 2 (VMAT2).  (See Zhang H, et 
al. and Gubernator NG, et al.) 
 
Paid Research Intern Jun 2005 – May 2007 
 Lab of Frank Fanqing Chen, PhD, Staff Scientist 
 Lawrence Berkeley National Labs 
 
Paid Research Intern Jun 2006 – Aug 2006 




 Berlex Laboratories, Richmond, CA (now Bayer) 
 
Paid Research Intern Summer 2003, 2004 
 Lab of Mitchell Singer, Professor of Microbiology 
 University of California, Davis 
 
Honors and Awards  
 
Medical Scientist Training Program Fellowship 2011-present 
Johns Hopkins University School of Medicine 
 
Recipient, Foundation for Advanced Research in the  2013-2014 
Medical Sciences (FARMS) Fellowship  
 
Dean’s List, College of Letters and Sciences, UC Berkeley 2003-2007 
Awarded 6 of 8 semesters; acknowledges the top 4% of students in the 




Mukherjee-Clavin B, Kim Y, Lim H, Choi I, Oh Y, Lannon B, Eggan K, Hoke 
A, Studer L, and Lee G. Three congruent human Schwann cell models of 
CMT1A 1 reveal a converged phenotype. (Under revision for resubmission) 
 
Mukherjee-Clavin B, Tomishima M, Lee G.  Current approaches for efficient 
genetic editing in human pluripotent stem cells.  Frontiers in Biology.  2013 
Oct; 8(5): 461-467. 
 
Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi 
IY, Mukherjee-Clavin B, Djaballah H, Studer L.  Large-scale screening 
using familial dysautonomia induced pluripotent stem cells identifies 
compounds that rescue IKBKAP expression.  Nature Biotechnology.  2012 
Dec; 30(12):1244-8 
 
Sun C, Su KH, Valentine J, Rosa-Bauza YT, Ellman JA, Elboudwarej O, 
Mukherjee B, Craik CS, Shuman MA, Chen FF, Zhang X.  Time-resolved 
single-step protease activity quantification using nanoplasmonic resonator 





Zhang H, Gubernator NG, Yue M, Staal RG, Mosharov EV, Pereira D, 
Balsanek V, Vadola PA, Mukherjee B, Edwards RH, Sulzer D, Sames 
D.  Dopamine release at individual presynaptic terminals visualized with 
FFNs.  J Vis Exp. 2009 Aug 31;(30). 
 
Gubernator NG, Zhang H, Staal RG, Mosharov EV, Pereira DB, Yue M, 
Balsanek V, Vadola PA, Mukherjee B, Edwards RH, Sulzer D, Sames 
D.  Fluorescent false neurotransmitters visualize dopamine release from 
individual presynaptic terminals.  Science. 2009 Jun 12; 324(5933):1441-4. 
 
Tang YJ, Ashcroft JM, Chen D, Min G, Kim C, Mukherjee B, Larabell C, 
Keasling JD, Chen FF.  Charge-associated effects of fullerene derivatives on 
microbial structural integrity and central metabolism.  Nano Letters. 2007 
Mar; 7(3): 754-60. 
 
Liu GL, Yin Y, Kunchakarra S, Mukherjee B, Gerion D, Jett SD, Bear DG, 
Gray JW, Alivisatos AP, Lee LP, Chen FF. A nanoplasmonic molecular ruler for 
measuring nuclease activity and DNA footprinting.  Nature Nanotechnology. 
2006 Oct; 1(1): 47-52. 
 
Pham VD, Shebelut CW, Mukherjee B, Singer M. 2005. RasA is required for 





Bipasha Mukherjee-Clavin, Carolina Montaño, Neil M. Neumann and Wan 
R. Yang.  U.S. must restore biomedical research funding. Baltimore Sun. Sep 
17, 2013.  
 
Anirudh Ramesh, Karlo Perica, Meghana Desale, Bipasha Mukherjee, 
Stephanie McLaughlin.  A great victory, but the work is not done.  Baltimore 







Founder and co-leader, Association of Women Student MD/PhDs Mar 2012 - 
present 
 Longitudinal attrition of women physician-scientists across all stages of 
training and career development is a well-established phenomenon, yet the 
factors leading contributing to this phenomenon are often not well 
understood.  Several colleagues, faculty, and I came together to found an 
organization dedicated to addressing barriers to women’s advancement and 
promoting women’s important roles as leaders and vital contributors to the 
fields of science and medicine. My roles includes mentorship and outreach to 
undergraduates considering pursuing an MD/PhD, organizing networking 
events with junior and senior female faculty, and recruiting male peer and 
faculty allies.   
 In Feb 2016, I am also chairing a full day event in which Jo Handelsman, 
Associate Director of Science at the White House, interfaced with Johns 
Hopkins graduate students, faculty, and senior leadership to discuss her 
research findings regarding unconscious bias in academia as well as her 
policy efforts to promote gender equality.  This was part of the annual 
Catherine DeAngelis Lectureship to recognize women in science, and event 
became one of the capstone events of the Johns Hopkins School of Medicine 
Office of Women in Science and Medicine and of the Office of Faculty Affairs. 
 
Founder and co-leader, MD/PhD Student Advisory Board Jan 2012 - 
present 
 Out of a desire to promote greater student involvement in the MD/PhD 
program, several students and I came together to form this advisory board.  
Together, we have implemented a faculty-student mentorship program, 
increased the diversity of our invited speakers, created programming on 
professional development for physician-scientists, and succeeding in 
fostering a collegial and inclusive atmosphere within our program. 
 
 
Leadership Board, Maryland Doctors for America Sep 2009 - 
2014 
 Doctors for America is an organization dedicated to promoting health 
care access for all, as well as educating the public about the Affordable Care 
Act (ACA).  Prior to the passage of the ACA, I attended town halls, organized 
phone banks, lobbied my representatives, wrote op-eds in local papers, and 
spoke to the media to encourage the passage of a comprehensive health 




series of educational materials to better inform both patients and health care 




Neuroanatomy dry and wet labs, JHUSOM 2015 
Cell Physiology, JHUSOM 2012 




Bharatanatyam (classical Indian) dancer for 14 years 
Sourdough yeast culture and baking 
Traveling domestically and internationally 
 
